U.S. patent application number 14/705433 was filed with the patent office on 2015-08-20 for use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell.
This patent application is currently assigned to ALNYLAM PHARMACEUTICALS, INC.. The applicant listed for this patent is ALNYLAM PHARMACEUTICALS, INC.. Invention is credited to Tony GIORDANO, Catherine PACHUK, Chandrasekhar SATISHCHANDRAN.
Application Number | 20150232930 14/705433 |
Document ID | / |
Family ID | 26951433 |
Filed Date | 2015-08-20 |
United States Patent
Application |
20150232930 |
Kind Code |
A1 |
GIORDANO; Tony ; et
al. |
August 20, 2015 |
USE OF POST-TRANSCRIPTIONAL GENE SILENCING FOR IDENTIFYING NUCLEIC
ACID SEQUENCES THAT MODULATE THE FUNCTION OF A CELL
Abstract
Described herein are methods for identifying nucleic acid
sequences that modulate the function of a cell, the expression of a
gene in a cell, or the biological activity of a target polypeptide
in a cell. The methods involve the use of double stranded RNA
expression libraries, double stranded RNA molecules, and
post-transcriptional gene silencing techniques.
Inventors: |
GIORDANO; Tony;
(Phoenixville, PA) ; PACHUK; Catherine; (Lansdale,
PA) ; SATISHCHANDRAN; Chandrasekhar; (Lansdale,
PA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ALNYLAM PHARMACEUTICALS, INC. |
Cambridge |
MA |
US |
|
|
Assignee: |
ALNYLAM PHARMACEUTICALS,
INC.
Cambridge
MA
|
Family ID: |
26951433 |
Appl. No.: |
14/705433 |
Filed: |
May 6, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10762395 |
Jan 22, 2004 |
9051566 |
|
|
14705433 |
|
|
|
|
10062707 |
Jan 31, 2002 |
|
|
|
10762395 |
|
|
|
|
60265805 |
Jan 31, 2001 |
|
|
|
60339260 |
Oct 26, 2001 |
|
|
|
Current U.S.
Class: |
506/2 ; 435/29;
435/6.12; 435/6.13; 435/7.1; 435/7.92; 435/8; 506/10 |
Current CPC
Class: |
C12Q 1/6897 20130101;
G01N 2333/565 20130101; C12N 15/1086 20130101; C12Q 2600/178
20130101; G01N 2333/56 20130101; C12N 15/1096 20130101; C12Q
2600/136 20130101; G01N 33/6866 20130101; C12Q 1/6876 20130101;
G01N 2500/10 20130101; G01N 2333/57 20130101; C12Q 2600/16
20130101 |
International
Class: |
C12Q 1/68 20060101
C12Q001/68; G01N 33/68 20060101 G01N033/68 |
Claims
1. A method for identifying a nucleic acid that modulates the
function of a vertebrate cell, said method comprising the steps of:
(a) transforming a population of vertebrate cells with a double
stranded RNA expression library, wherein at least two cells of said
population of cells are each transformed with a different nucleic
acid from said double stranded RNA expression library, wherein said
transformed nucleic acid is capable of forming double stranded RNA,
and wherein said transformation and said formation of double
stranded RNA are carried out under conditions that inhibit or
prevent an interferon response or a double stranded RNA stress
response; (b) selecting a vertebrate cell in which said nucleic
acid is expressed in said cell; and (c) assaying for a modulation
in the function of said cell, wherein said LI modulation identifies
a nucleic acid that modulates the function of said vertebrate
cell.
2. A method for identifying a nucleic acid that modulates
expression of a target nucleic acid in a vertebrate cell, said
method comprising the steps of: (a) transforming a population of
vertebrate cells with a double stranded RNA expression library,
wherein at least two cells of said population of cells are each
transformed with a different nucleic acid from said double stranded
RNA expression library, wherein said transformed nucleic acid is
capable of forming double stranded RNA, and wherein said
transformation and said formation of double stranded-RNA are
carried out under conditions that inhibit or prevent an interferon
response or a double stranded RNA stress response; (b) selecting a
vertebrate cell in which said nucleic acid is expressed in said
cell; and (c) assaying for a modulation in the expression of a
target nucleic acid in said cell, wherein said modulation
identifies a nucleic acid that modulates expression of said target
nucleic acid.
3. A method for identifying a nucleic acid that modulates the
biological activity of a target polypeptide in a vertebrate cell,
said method comprising the steps of: (a) transforming a population
of vertebrate cells with a double stranded RNA expression library,
wherein at least two cells of said population of cells are each
transformed with a different nucleic acid from said double stranded
RNA expression library, wherein said transformed nucleic acid is
capable of forming double stranded RNA, and wherein said
transformation and said formation of double stranded RNA are
carried out under conditions that inhibit or prevent an interferon
response or a double stranded RNA stress response; (b) selecting
for a vertebrate cell in which said nucleic acid is expressed in
said cell; and (c) assaying for a modulation in the biological
activity of a target polypeptide in said cell, wherein said
modulation identifies a nucleic acid that modulates the biological
activity of said target polypeptide.
4. The method of claim 1, wherein at most one nucleic acid is
stably integrated into a chromosome of each cell.
5. The method of claim 1, said method further comprising: (d)
identifying said nucleic acid by amplifying said nucleic acid and
sequencing said amplified nucleic acid.
6. The method of claim 1, wherein, said double stranded RNA
expression library comprises cDNAs derived from said cells.
7. The method of claim 1, wherein said double stranded RNA
expression library comprises randomized nucleic acids.
8. The method of claim 1, wherein said double stranded RNA
expression library is a nuclear double stranded RNA expression
library.
9. The method of claim 1, wherein said double stranded RNA
expression library is a cytoplasmic double stranded RNA expression
library.
10. The method of claim 1, wherein said cell is a mammalian
cell.
11. The method of claim 10, wherein said cell is a human cell.
12. The method of claim 10, wherein said cell is selected from the
group consisting of a cancer cell, a cell of the immune system, a
stem cell, a neuronal cell, a muscle cell, and an adipocyte.
13. The method of claim 1, wherein said nucleic acid is contained
in a vector.
14. The method of claim 13, wherein said vector comprises an RNA
polymerase II promoter, an RNA polymerase I promoter, an RNA
polymerase III promoter, or a mitochondrial promoter.
15. The method of claim 13, wherein the sense strand and the
anti-sense strand of said double stranded RNA are transcribed from
the same nucleic acid using two convergent promoters.
16. The method of claim 13, wherein said nucleic acid comprises an
inverted repeat such that upon transcription said nucleic acid
forms a double stranded RNA.
17. The method of claim 1, wherein said assaying comprises
measuring an event selected from the group consisting of cell
motility, apoptosis, cell growth, cell invasion, vascularization,
cell cycle events, cell differentiation, cell dedifferentiation,
neuronal cell regeneration, and the ability of a cell to support
viral replication.
18. The method of claim 1, wherein said double stranded RNA is
between 5 and 100 nucleotides in length, inclusive.
19. The method of claim 1, wherein said double stranded RNA is at
least 100 nucleotides in length.
20. The method of claim 19, wherein said double stranded RNA is at
least 250 nucleotides in length.
21. The method of claim 20, wherein said double stranded RNA is at
least 500 nucleotides in length.
22. The method of claim 21, wherein said double stranded RNA is at
least 1000 nucleotides in length.
23. A method for identifying a nucleic acid that modulates the
function of a vertebrate cell, said method comprising the steps of:
(a) transforming a population of vertebrate cells with a double
stranded RNA under conditions that inhibit or prevent an interferon
response or a double stranded RNA stress response; (b) selecting a
vertebrate cell in which said double stranded RNA is expressed; and
(c) assaying for a modulation in the function of said cell, wherein
said modulation identifies a nucleic acid that modulates the
function of said cell.
24. A method for identifying a nucleic acid that modulates
expression of a target nucleic acid in a vertebrate cell, said
method comprising the steps of: (a) transforming a population of
vertebrate cells with a double stranded RNA under conditions that
inhibit or prevent an interferon response or a double stranded RNA
stress response; (b) selecting a vertebrate cell in which said
double stranded RNA is expressed; and (c) assaying for a modulation
in the expression of a target nucleic acid in said cell, wherein
said modulation identifies a nucleic acid that modulates expression
of said target nucleic acid.
25. A method for identifying a nucleic acid that modulates the
biological activity of a target polypeptide in a vertebrate cell,
said method comprising the steps of: (a) transforming a population
of vertebrate cells with a double stranded RNA under conditions
that inhibit or prevent an interferon response or a double stranded
RNA stress response; (b) selecting a vertebrate cell in which said
double stranded RNA is expressed; and (c) assaying for a modulation
in the biological activity of a target polypeptide in said cell,
wherein said modulation identifies a nucleic acid that modulates
the biological activity of said target polypeptide.
26. The method of claim 23, said method further comprising: (d)
identifying said nucleic acid by amplifying said nucleic acid and
sequencing said amplified nucleic acid.
27. The method of claim 23, wherein said double stranded RNA is
derived from said cells.
28. The method of claim 23, wherein said double stranded RNA is
between 5 and 100 nucleotides in length, inclusive.
29. The method of claim 23, wherein said double stranded RNA is at
least 100 nucleotides in length.
30. The method of claim 29, wherein said double stranded RNA is at
least 250 nucleotides in length.
31. The method of claim 30, wherein said double stranded RNA is at
least 500 nucleotides in length.
32. The method of claim 31, wherein said double stranded RNA is at
least 1000 nucleotides in length.
33. The method of claim 23, wherein each cell is transformed with
at most one double stranded RNA.
34. The method of claim 23, wherein said cell is a mammalian
cell.
35. The method of claim 34, wherein said cell is a human cell.
36. The method of claim 23, wherein said population is transformed
with at least 100 different double stranded RNAs.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of the filing date of
U.S. provisional applications 60/265,805, filed Jan. 31, 2001, and
60/339,260, filed Oct. 26, 2001.
BACKGROUND OF THE INVENTION
[0002] The invention relates to methods for identifying nucleic
acid sequences that modulate the function of a cell, by the use of
post-transcriptional gene silencing.
[0003] Double stranded RNA (dsRNA) has been shown to induce
sequence-specific gene silencing in a number of different
organisms. Gene silencing can occur through various mechanisms, one
of which is post-transcriptional gene silencing (PTGS). In
post-transcriptional gene silencing, transcription of the target
locus is not affected, but the RNA half-life is decreased. The
mechanisms by which PTGS occurs are not yet clear. Exogenous dsRNA
has been shown to act as a potent inducer of PTGS in nematodes,
trypanosomes, and insects. In addition, studies in C. elegans and
Drosophila show that a few molecules of dsRNA per cell are
sufficient to trigger a PTGS response. Furthermore, studies in mice
have demonstrated that dsRNA can interfere with the expression of
genes in mouse embryos.
[0004] There exists a need to identify molecules that selectively
regulate the expression of genes in vertebrate cells without the
associated toxicity of the interferon response. Such regulation
should allow the downregulation of expression from genes whose gene
products are detrimental to the cells.
SUMMARY OF THE INVENTION
[0005] In general the invention features high throughput methods of
using PTGS to identify a nucleic acid sequence that modulates the
function of a cell, gene expression of a target nucleic acid, or
the biological activity of a target polypeptide. The method
involves the use of specially constructed cDNA libraries derived
from a cell, for example, a primary cell or a cell line that has an
observable phenotype or biological activity, (e.g., an activity
mediated by a target polypeptide or altered gene expression), that
are transfected into cells to inhibit gene expression. This
inhibition of gene expression alters the function of a cell, gene
expression of a target nucleic acid, or the biological activity of
a target polypeptide, and the nucleic acid sequence responsible for
the modulation can be readily identified. The method may also
utilize randomized nucleic acid sequences or a given sequence for
which the function is not known. Although the use of PTGS as a
validation strategy is known in the art, its use in screening
techniques, as described herein, is novel.
[0006] Accordingly, in a first aspect, the invention features a
method for identifying a nucleic acid sequence that modulates the
function of a cell. The method involves: (a) transforming a
population of cells with a double stranded RNA expression library,
where the library is derived from the cells, where at least two
cells of the population of cells are each transformed with a
different nucleic acid from the double stranded RNA expression
library, and where the nucleic acid is capable of forming double
stranded RNA; (b) optionally selecting for a cell in which the
nucleic acid is expressed in the cell; and (c) assaying for a
modulation in the function of the cell, wherein a modulation
identifies a nucleic acid sequence that modulates the function of a
cell.
[0007] In a desirable embodiment of the first aspect of the
invention, assaying for a modulation in the function of a cell
comprises measuring cell motility, apoptosis, cell growth, cell
invasion, vascularization, cell cycle events, cell differentiation,
cell dedifferentiation, neuronal cell regeneration, or the ability
of a cell to support viral replication.
[0008] In a second aspect, the invention features a method for
identifying a nucleic acid sequence that modulates expression of a
target nucleic acid in a cell. The method involves: (a)
transforming a population of cells with a double stranded RNA
expression library, where the library is derived from the cells,
where at least two cells of the population of cells are each
transformed with a different nucleic acid from the double stranded
RNA expression library, and where the nucleic acid is capable of
forming double stranded RNA; (b) optionally selecting for a cell in
which the nucleic acid is expressed in the cell; and (c) assaying
for a modulation in the expression of a gene in the cell, where a
modulation identifies a nucleic acid sequence that modulates
expression of a target nucleic acid in a cell.
[0009] In a desirable embodiment of the second aspect of the
invention, the target nucleic acid is assayed using DNA array
technology.
[0010] In a third aspect, the invention features a method for
identifying a nucleic acid sequence that modulates the biological
activity of a target polypeptide in a cell. The method involves:
(a) transforming a population of cells with a double stranded RNA
expression library, where the library is derived from the cells,
where at least two cells of the population of cells are each
transformed with a different nucleic acid from the double stranded
RNA expression library, and where the nucleic acid is capable of
forming double stranded RNA; (b) optionally selecting for a cell in
which the nucleic acid is expressed in the cell; and (c) assaying
for a modulation in the biological activity of a target polypeptide
in the cell, wherein a modulation identifies a nucleic acid
sequence that modulates the biological activity of a target
polypeptide.
[0011] In one embodiment of any of the above aspects of the
invention, in transforming step (a), the nucleic acid is stably
integrated into a chromosome of the cell. Integration of the
nucleic acid may be random or site-specific. Desirably integration
is mediated by recombination or retroviral insertion. In addition,
desirably a single copy of the nucleic acid is integrated into the
chromosome. In another embodiment of any of the above aspects of
the invention, in step (a) at least 50, more desirably 100; 500;
1000; 10,000; or 50,000 cells of the population of cells are each
transformed with a different nucleic acid from the double stranded
RNA expression library. In other embodiments, the population of
cells is transformed with at least 5%, more desirably at least 25%,
50%, 75%, or 90%, and most desirably at least 95% of the double
stranded RNA expression library. In yet another embodiment, the
method further involves: (d) identifying the nucleic acid sequence
by amplifying and cloning the sequence. Desirably amplification of
the sequence involves the use of the polymerase chain reaction
(PCR).
[0012] In other embodiments of any of the above aspects of the
invention, the double stranded RNA expression library contains
cDNAs or randomized nucleic acids. The double stranded RNA
expression library may be a nuclear double stranded RNA expression
library, in which case the double stranded nucleic acid is made in
the nucleus. Alternatively, the double stranded RNA expression
library may be a cytoplasmic double stranded RNA expression
library, in which case the double stranded nucleic acid is made in
the cytoplasm. In addition, the nucleic acid from the double
stranded RNA expression library may be made in vitro or in vivo. In
addition, the identified nucleic acid sequence may be located in
the cytoplasm of the cell.
[0013] In still another embodiment of any of the above aspects of
the invention, the nucleic acid is contained in a vector, for
example a double stranded RNA expression vector. The vector may
then be transformed such that it is stably integrated into a
chromosome of the cell, or it may function as an episomal
(non-integrated) expression vector within the cell. In one
embodiment, a vector that is integrated into a chromosome of the
cell contains a promoter operably linked to a nucleic acid encoding
a hairpin or double stranded RNA. In another embodiment, the vector
does not contain a promoter operably linked to a nucleic acid
encoding a double stranded RNA. In this later embodiment, the
vector integrates into a chromosome of a cell such that an
endogenous promoter is operably linked to a nucleic acid from the
vector that encodes a double stranded RNA. Desirably, the double
stranded RNA expression vector comprises at least one RNA
polymerase II promoter, for example, a human CMV-immediate early
promoter (HCMV-IE) or a simian CMV (SCMV) promoter, at least one
RNA polymerase I promoter, or at least one RNA polymerase III
promoter. The promoter may also be a T7 promoter, in which case,
the cell further comprises T7 polymerase. Alternatively, the
promoter may be an SP6 promoter, in which case, the cell further
comprises SP6 polymerase. The promoter may also be one convergent
T7 promoter and one convergent SP6 promoter. A cell may be made to
contain T7 or SP6 polymerase by transforming the cell with a T7
polymerase or an SP6 polymerase expression plasmid, respectively.
In some embodiments, a T7 promoter or a RNA polymerase III promoter
is operably linked to a nucleic acid that encodes a small double
stranded RNA (e.g., a double stranded RNA that is less than 200,
150, 100, 75, 50, or 25 nucleotides in length). In other
embodiments, the promoter is a mitochondrial promoter that allows
cytoplasmic transcription of the nucleic acid in the vector (see,
for example, the mitochondrial promoters described in WO 00/63364,
filed Apr. 19, 2000). Alternatively, the promoter is an inducible
promoter, such as a lac (Cronin et al. Genes & Development 15:
1506-1517, 2001), ara (Khlebnikov et al., J Bacteriol. 2000
December; 182(24):7029-34), ecdysone (Rheogene, www.rheogene.com),
RU48 (mefepristone) (corticosteroid antagonist) (Wang X J, Liefer K
M, Tsai S, O'Malley B W, Roop D R, Proc Natl Acad Sci USA. 1999
Jul. 20; 96(15):8483-8), or tet promoter (Rendal et al., Hum Gene
Ther. 2002 January; 13(2):335-42, and Larnartina et al., Hum Gene
Ther. 2002 January; 13(2):199-210) or a promoter disclosed in WO
00/63364, filed Apr. 19, 2000.
[0014] In desirable embodiments, the inducible promoter is not
induced until all the episomal vectors are eliminated from the
cell. The vector may also comprise a selectable marker. In
addition, these vectors may be used in combination with methods
that inhibit or prevent an interferon response or double stranded
RNA stress response, as described herein.
[0015] Desirably in a vector for use in any of the above aspects of
the invention, the sense strand and the antisense strand of the
nucleic acid sequence are transcribed from the same nucleic acid
sequence using two convergent promoters. It another desirable
embodiment, in a vector for use in any of the above aspects of the
invention, the nucleic acid sequence comprises an inverted repeat,
such that upon transcription, the nucleic acid forms a double
stranded RNA.
[0016] In still other embodiments of any of the above aspects of
the invention, the cell and the vector each further comprise a loxP
site and site-specific integration of the nucleic acid into a
chromosome of the cell occurs through recombination between the
loxP sites. In addition, step (b) of any of the above aspects of
the invention further involves rescuing the nucleic acid through
Cre-mediated double recombination.
[0017] In still further embodiments of any of the above aspects of
the invention, the identified nucleic acid sequence is located in
the nucleus of the cell. Alternatively, the identified nucleic acid
sequence may be located in the cytoplasm of the cell.
[0018] In yet another embodiment of any of the above aspects of the
invention, the nucleic acid from the double stranded RNA expression
library is at least 100, 500, 600, or 1000 nucleotides in length.
In other embodiments of any of the above aspects of the invention,
the nucleic acid from the double stranded RNA expression library is
at least 10, 20, 30, 40, 50, 60, 70, 80, or 90 nucleotides in
length. In yet other embodiments, the number of nucleotides in the
nucleic acid from the double stranded RNA expression library is
between 5-100 nucleotides, 15-100 nucleotides, 20-95 nucleotides,
25-90 nucleotides, 35-85 nucleotides, 45-80 nucleotides, 50-75
nucleotides, or 55-70 nucleotides, inclusive. In still other
embodiments, the number of nucleotides in the nucleic acid from the
double stranded RNA expression library is contained in one of the
following ranges: 5-15 nucleotides, 15-20 nucleotides, 20-25
nucleotides, 25-35 nucleotides, 35-45 nucleotides,
45-60-nucleotides, 60-70 nucleotides, 70-80 nucleotides, 80-90
nucleotides, or 90-100 nucleotides, inclusive. In other
embodiments, the nucleic acid contains less than 50,000; 10,000;
5,000; or 2,000 nucleotides. In addition, the nucleic acid from the
double stranded RNA expression library may contain a sequence that
is less than a full length RNA sequence.
[0019] In still further embodiments of any of the above aspects of
the invention, the cell is a plant cell or an animal cell.
Desirably the animal cell is a vertebrate or mammalian cell, for
example, a human cell. The cell may be ex vivo or in vivo. The cell
may be a gamete or a somatic cell, for example, a cancer cell, a
stem cell, a cell of the immune system, a neuronal cell, a muscle
cell, or an adipocyte.
[0020] Transformation/transfection of the cell may occur through a
variety of means including, but not limited to, lipofection,
DEAE-dextran-mediated transfection, microinjection, protoplast
fusion, calcium phosphate precipitation, viral or retroviral
delivery, electroporation, or biolistic transformation. The RNA or
RNA expression vector (DNA) may be naked RNA or DNA or local
anesthetic complexed RNA or DNA (Pachuk et al., Biochim. Biophys.
Acta 1468:20-30, 2000). In another embodiment, the cell is not a C.
elegans cell. Desirably the vertebrate or mammalian cell has been
cultured for only a small number of passages (e.g., less than 30
passages of a cell line that has been directly obtained from
American Type Culture Collection), or are primary cells. Desirably,
the vertebrate or mammalian cell is transformed with nucleic acids
that are not complexed with cationic lipids.
[0021] In yet another embodiment of any of the above aspects of the
invention, the cell is derived from a parent cell, and is generated
by: (a) transforming a population of parent cells with a
bicistronic plasmid expressing a selectable marker and a reporter
gene, and comprising a loxP site; (b) selecting for a cell in which
the plasmid is stably integrated; and (c) selecting for a cell in
which one copy of the plasmid is stably integrated in a
transcriptionally active locus. Desirably the selectable marker is
G418 and the reporter gene is green fluorescent protein (GFP).
[0022] In still another embodiment of the above aspects of the
invention, generation of the double stranded expression library
comprises: (a) isolating RNA from a cell; (b) synthesizing cDNAs
from the RNA of step (a); and (c) cloning each cDNA into a vector.
Desirably cDNA synthesis is optimized and/or size selected for the
generation and/or selection of cDNAs that are at least 100, 500,
600, or 1000 nucleotides in length. In other embodiments, the cDNAs
are least 10, 20, 30, 40, 50, 60, 70, 80, or 90 nucleotides in
length. In yet other embodiments, the number of nucleotides in the
cDNAs is between 5-100 nucleotides, 15-100 nucleotides, 20-95
nucleotides, 25-90 nucleotides, 35-85 nucleotides, 45-80
nucleotides, 50-75 nucleotides, or 55-70 nucleotides, inclusive. In
still other embodiments, the number of nucleotides in the cDNAs is
contained in one of the following ranges: 5-15 nucleotides, 15-20
nucleotides, 20-25 nucleotides, 25-35 nucleotides, 35-45
nucleotides, 45-60 nucleotides, 60-70 nucleotides, 70-80
nucleotides, 80-90 nucleotides, or 90-100 nucleotides, inclusive.
In other embodiments, the cDNAs contain less than 50,000; 10,000;
5,000; or 2,000 nucleotides. In addition, the cDNA may encode an
RNA fragment that is less than full length. Desirably the vector
comprises two convergent T7 promoters, two convergent SP6
promoters, or one convergent T7 promoter and one convergent SP6
promoter, a selectable marker, and/or a loxP site.
[0023] In an additional embodiment of any of the above aspects of
the invention, the method is carried out under conditions that
inhibit or prevent an interferon response or double stranded RNA
stress response.
[0024] In a fourth aspect, the invention features a method for
identifying a nucleic acid sequence that modulates the function of
a cell, involving: (a) transforming a population of cells with a
double stranded RNA that is derived from the cells; (b) optionally
selecting for a cell in which the nucleic acid is expressed; and
(c) assaying for a modulation in the function of the cell, wherein
the modulation identifies a nucleic acid sequence that modulates
the function of a cell, wherein the method is desirably carried out
under conditions that inhibit or prevent an interferon response or
double stranded RNA stress response.
[0025] In a desirable embodiment of the fourth aspect of the
invention, assaying for a modulation in the function of a cell
comprises measuring cell motility, apoptosis, cell growth, cell
invasion, vascularization, cell cycle events, cell differentiation,
cell dedifferentiation, neuronal cell regeneration, or the ability
of a cell to support viral replication.
[0026] In a fifth aspect, the invention features a method for
identifying a nucleic acid sequence that modulates expression of a
target nucleic acid in a cell, involving: (a) transforming a
population of cells with a double stranded RNA that is derived from
the cells; (b) optionally selecting for a cell in which the nucleic
acid is expressed; and (c) assaying for a modulation in the
expression of the gene in the cell, wherein the modulation
identifies a nucleic acid sequence that modulates expression of a
target nucleic acid in a cell, wherein the method is desirably
carried out under conditions that inhibit or prevent an interferon
response or double stranded RNA stress response.
[0027] In a desirable embodiment of the fifth aspect of the
invention, the target nucleic acid is assayed using DNA array
technology.
[0028] In a sixth aspect, the invention features a method for
identifying a nucleic acid sequence that modulates the biological
activity of a target polypeptide in a cell, involving: (a)
transforming a population of cells with a double stranded RNA that
is derived from the cells; (b) optionally selecting for a cell in
which the nucleic acid is expressed in the cell; and (c) assaying
for a modulation in the biological activity of a target polypeptide
in the cell, wherein the modulation identifies a nucleic acid
sequence that modulates the biological activity of a target
polypeptide in a cell, wherein the method is desirably carried out
under conditions that inhibit or prevent an interferon response or
double stranded RNA stress response.
[0029] In a seventh aspect, the invention features a method for
identifying a nucleic acid sequence that modulates the function of
a cell, involving: (a) transforming a population of cells with a
double stranded RNA; (b) optionally selecting for a cell in which
the nucleic acid is expressed; and (c) assaying for a modulation in
the function of the cell. Desirably, the modulation identifies a
nucleic acid sequence that modulates the function of a cell,
wherein the method is desirably carried out under conditions that
or prevent an interferon response or double stranded RNA stress
response.
[0030] In a desirable embodiment of the seventh aspect of the
invention, assaying for a modulation in the function of a cell
comprises measuring cell motility, apoptosis, cell growth, cell
invasion, vascularization, cell cycle events, cell differentiation,
cell dedifferentiation, neuronal cell regeneration, or the ability
of a cell to support viral replication.
[0031] In a eighth aspect, the invention features a method for
identifying a nucleic acid sequence that modulates expression of a
target nucleic acid in a cell, involving: (a) transforming a
population of cells with a double stranded RNA; (b) optionally
selecting for a cell in which the nucleic acid is expressed; and
(c) assaying for a modulation in the expression of the gene in the
cell, wherein the modulation identifies a nucleic acid sequence
that modulates expression of a target nucleic acid in a cell.
Desirably, the method is carried out under conditions that inhibit
or prevent an interferon response or double stranded RNA stress
response.
[0032] In a desirable embodiment of the eighth aspect of the
invention, the target b nucleic acid is assayed using DNA array
technology.
[0033] In a ninth aspect, the invention features a method for
identifying a nucleic acid sequence that modulates the biological
activity of a target polypeptide in a cell, involving: (a)
transforming a population of cells with a double stranded RNA; (b)
optionally selecting for a cell in which the nucleic acid is
expressed in the cell; and (c) assaying for a modulation in the
biological activity of a target polypeptide in the cell, wherein
the modulation identifies a nucleic acid sequence that modulates
the biological activity of a target polypeptide in a cell.
Desirably, the method is carried out under conditions that inhibit
or prevent an interferon response double stranded RNA stress
response.
[0034] In one embodiment of any of the above aspects of the
invention, in step (a) at least 2, more desirably 50; 100; 500;
1000; 10,000; or 50,000 cells of the population of cells are each
transformed with a different double stranded RNA from a double
stranded RNA expression library. Desirably, at most one double
stranded RNA is inserted into each cell. In other embodiments, the
population of cells is transformed with at least 5%, more desirably
at least 25%, 50%, 75%, or 90%, and most desirably, at least 95% of
the double stranded RNA expression library. In still another
embodiment of any of the fourth, fifth, or sixth aspects of the
invention, the method further involves: (d) identifying the nucleic
acid sequence by amplifying and cloning the sequence. Desirably
amplification of the sequence involves the use of the polymerase
chain reaction (PCR).
[0035] In a tenth aspect, the invention features a cell or a
population of cells that expresses a double stranded RNA that (i)
modulates a function of the cell, (ii) modulates the expression of
a target nucleic acid (e.g., an endogenous or pathogen gene) in the
cell, and/or (iii) modulates the biological activity of a target
protein (e.g., an endogenous or pathogen protein) in the cell.
Desirably, the cell contains only one molecular species of double
stranded RNA or only one copy of a double stranded RNA expression
vector (e.g., a stably integrated vector). Desirably, the cell or
population of cells is produced using one or more methods of the
invention. In other embodiments, the double stranded RNA is
expressed under conditions that inhibit or prevent an interferon
response or a double stranded RNA stress response.
[0036] In other embodiments of any of the fourth, fifth, sixth,
seventh, eighth, ninth, or tenth aspects of the invention, the
double stranded RNA is derived from cDNAs or randomized nucleic
acids. In addition, the double stranded RNA may be a cytoplasmic
double stranded RNA, in which case the double stranded nucleic acid
is made in the cytoplasm. The double stranded RNA may be made in
vitro or in vivo. In addition, the identified nucleic acid sequence
may be located in the cytoplasm of the cell.
[0037] In still another embodiment of any of the fourth, fifth,
sixth, seventh, eighth, ninth, or tenth aspects of the invention,
the nucleic acid is contained in a vector, for example, a double
stranded RNA expression vector that is capable of forming a double
stranded RNA. Desirably the double stranded RNA expression vector
comprises at least one promoter. The promoter may be a T7 promoter,
in which case, the cell further comprises T7 polymerase.
Alternatively, the promoter may be an SP6 promoter, in which case,
the cell further comprises SP6 polymerase. The promoter may also be
one convergent T7 promoter and one convergent SP6 promoter. A cell
may be made to contain T7 or SP6 polymerase by transforming the
cell with a T7 polymerase or an SP6 polymerase expression plasmid,
respectively. The vector may also comprise a selectable marker, for
example hygromycin.
[0038] Desirably in a vector for use in any of the fourth, fifth,
sixth, seventh, eighth, ninth, or tenth aspects of the invention,
the sense strand and the antisense strand of the nucleic acid
sequence are transcribed from the same nucleic acid sequence using
two convergent promoters. In another desirable embodiment, in a
vector for use in any of the above aspects of the invention, the
nucleic acid sequence comprises an inverted repeat, such that upon
transcription, the nucleic acid forms a double stranded RNA.
[0039] In yet another embodiment of any of the fourth, fifth,
sixth, seventh, eighth, ninth, or tenth aspects of the invention,
the double stranded RNA is at least 100, 500, 600, or 1000
nucleotides in length. In other embodiments of any of the fourth,
fifth, or sixth aspects of the invention, the double stranded RNA
is at least 10, 20, 30, 40, 50, 60, 70, 80, or 90 nucleotides in
length. In yet other embodiments, the number of nucleotides in the
double stranded RNA is between 5-100 nucleotides, 15-100
nucleotides, 20-95 nucleotides, 25-90 nucleotides, 35-85
nucleotides, 45-80 nucleotides, 50-75 nucleotides, or 55-70
nucleotides, inclusive. In still other embodiments, the number of
nucleotides in the double stranded RNA is contained in one of the
following ranges: 5-15 nucleotides, 15-20 nucleotides, 20-25
nucleotides, 25-35 nucleotides, 35-45 nucleotides, 45-60
nucleotides, 60-70 nucleotides, 70-80 nucleotides, 80-90
nucleotides, or 90-100 nucleotides, inclusive. In other
embodiments, the double stranded RNA contains less than 50,000;
10,000; 5,000; or 2,000 nucleotides. In addition, the double
stranded RNA may contain a sequence that is less than a full length
RNA sequence.
[0040] In still further embodiments of any of the fourth, fifth,
sixth, seventh, eighth, ninth, or tenth aspects of the invention,
the cell is a plant cell or an animal cell. Desirably the animal
cell is a vertebrate or mammalian cell, for example, a human cell.
The cell may be ex vivo or in vivo. The cell may be a gamete or a
somatic cell, for example, a cancer cell, a stem cell, a cell of
the immune system, a neuronal cell, a muscle cell, or an
adipocyte.
[0041] In other embodiments of any of the first, second, third,
seventh, eighth, ninth, or tenth aspects of the invention, the
double stranded RNA is derived from a cell or a population of cells
and used to transform another cell population of either the same
cell type or a different cell type. In desirable embodiments, the
transformed cell population contains cells of a cell type that is
related to the cell type of the cells from which the double
stranded RNA was derived (e.g., the transformation of cells of one
neuronal cell type with the double stranded RNA derived from cells
of another neuronal cell type). In yet other embodiments of any of
these aspects, the double stranded RNA contains one or more
contiguous or non-contiguous positions that are randomized (e.g.,
by chemical or enzymatic synthesis using a mixture of nucleotides
that may be added at the randomized position). In still other
embodiments, the double stranded RNA is a randomized nucleic acid
in which segments of ribonucleotides and/or deoxyribonucleotides
are ligated to form the double stranded RNA.
[0042] In other embodiments of any of various aspects of the
invention, the double stranded RNA specifically hybridizes to a
target nucleic acid but does not substantially hybridize to
non-target molecules, which include other nucleic acids in the cell
or biological sample having a sequence that is less than 99, 95,
90, 80, or 70% identical or complementary to that of the target
nucleic acid. Desirably, the amount of the these non-target
molecules hybridized to, or associated with, the double stranded
RNA, as measured using standard assays, is 2-fold, desirably
5-fold, more desirably 10-fold, and most desirably 50-fold lower
than the amount of the target nucleic acid hybridized to, or
associated with, the double stranded RNA. In other embodiments, the
amount of a target nucleic acid hybridized to, or associated with,
the double stranded RNA, as measured using standard assays, is
2-fold, desirably 5-fold, more desirably 10-fold, and most
desirably 50-fold greater than the amount of a control nucleic acid
hybridized to, or associated with, the double stranded RNA.
Desirably, the double stranded RNA only hybridizes to one target
nucleic acid from a cell under denaturing, high stringency
hybridization conditions. In certain embodiments, the double
stranded RNA is substantially homologous (e.g., at least 80, 90,
95, 98, or 100% homologous) to only one target nucleic acid from a
cell. In other embodiments, the double stranded RNA is homologous
to multiple RNAs, such as RNAs from the same gene family. In yet
other embodiments, the double stranded RNA is homologous to
distinctly different mRNA sequences from genes that are similarly
regulated (e.g., developmental, chromatin remodeling, or stress
response induced). In other embodiments, the double stranded RNA is
homologous to a large number of RNA molecules, such as a double
stranded RNA designed to induce a stress response or apoptosis. In
other embodiments, the percent decrease in the expression of a
target nucleic acid is at least 2, 5, 10, 20, or 50 fold greater
than the percent decrease in the expression of a non-target or
control nucleic acid. Desirably, the double stranded RNA inhibits
the expression of a target nucleic acid but has negligible, if any,
effect on the expression of other nucleic acids in the cell.
Examples of control nucleic acids include nucleic acids with a
random sequence or nucleic acids known to have little, if any,
affinity for the double stranded RNA.
[0043] In other embodiments of any of various aspects of the
invention, at most one molecular species of double stranded RNA is
inserted into each cell. In other embodiments, at most one vector
is stably integrated into the genome of each cell. In various
embodiments, the double-stranded RNA is active in the nucleus of
the transformed cell and/or is active in the cytoplasm of the
transformed cell. In various embodiments, at least 1, 10, 20, 50,
100, 500, or 1000 cells or all of the cells in the population are
selected as cells that contain or express a double stranded RNA. In
some embodiments, at least 1, 10, 20, 50, 100, 500, or 1000 cells
or all of the cells in the population are assayed for a modulation
in the function of the cell, a modulation in the expression of a
target nucleic acid (e.g., an endogenous or pathogen gene) in the
cell, and/or a modulation in the biological activity of a target
protein (e.g., an endogenous or pathogen protein) in the cell.
[0044] In other embodiments, the double stranded RNA or double
stranded RNA expression vector is complexed with one or more
cationic lipids or cationic amphiphiles, such as the compositions
disclosed in U.S. Pat. No. 4,897,355 (Eppstein et al., filed Oct.
29, 1987), U.S. Pat. No. 5,264,618 (Felgner et al., filed Apr. 16,
1991) or U.S. Pat. No. 5,459,127 (Felgner et al., filed Sep. 16,
1993). In other embodiments, the double stranded RNA or double
stranded RNA expression vector is complexed with a
liposomes/liposomic composition that includes a cationic lipid and
optionally includes another component such as a neutral lipid (see,
for example, U.S. Pat. No. 5,279,833 (Rose), U.S. Pat. No.
5,283,185 (Epand), and U.S. Pat. No. 5,932,241). In yet other
embodiments, the double stranded RNA or double stranded RNA
expression vector is complexed with any other composition that is
devised by one of ordinary skill in the fields of pharmaceutics and
molecular biology.
[0045] Desirably, the double stranded RNA specifically hybridizes
to a target nucleic acid but does not substantially hybridize to
non-target molecules, which include other nucleic acids in the cell
or biological sample having a sequence that is less than 99, 95,
90, 80, or 70% identical to or complementary to that of the target
nucleic acid. In other embodiments, the percent decrease in the
expression of a target nucleic acid is at least 2, 5, 10, 20, or 50
fold greater than the percent decrease in the expression of a
non-target or control nucleic acid. Desirably, the double stranded
RNA inhibits the expression of the target nucleic acid but has
negligible, if any, effect on the expression of other nucleic acids
in the cell.
[0046] Transformation/transfection of the cell may occur through a
variety of means including, but not limited to, lipofection,
DEAE-dextran-mediated transfection, microinjection, protoplast
fusion, calcium phosphate precipitation, viral or retroviral
delivery, electroporation, or biolistic transformation. The RNA or
RNA expression vector (DNA) may be naked RNA or DNA or local
anesthetic complexed RNA or DNA (Pachuk et al., supra). In yet
another embodiment, the cell is not a C. elegans cell. Desirably
the vertebrate or mammalian cell has been cultured for only a small
number of passages (e.g., less than 30 passages of a cell line that
has been directly obtained from American Type Culture Collection),
or are primary cells. In addition, desirably the vertebrate or
mammalian cell is transformed with double stranded RNA that is not
complexed with cationic lipids.
[0047] The transcription systems described herein provide
advantages to other double stranded expression systems. Following
transformation of the double stranded RNA library, cells contain
hundreds to thousands of double stranded RNA expression cassettes,
with concomitant expression of that many expression cassettes. In
the double stranded RNA expression system of the present invention,
double stranded RNA (dsRNA) expression cassettes contained within
the expression-vector integrate into the chromosome of the
transfected cell. Desirably, every transformed cell integrates one
of the double stranded expression cassettes. Through expansion of
the transformed cell, episomal (non-integrated) expression vectors
are diluted out of the cell over time. Desirably no transcription
occurs until the episomal expression vectors are diluted out of the
cell, such that not more than 5 episomal vectors remain in the
cell. Most desirably, no transcription occurs until all of the
episomal vectors have been diluted out of the cell, and only the
integrated expression cassette remains. The time it takes for all
episomal vectors to be removed from the cell is proportional to the
replication rate of the transformed cell, and is generally on the
order of two to several weeks of cell culture and growth. The
numbers of copies of a dsRNA molecule in a transformed cell can be
determined using, for example, standard PCR techniques, and
thereby, the number of episomal vectors in a given cell can be
monitored.
[0048] Once a stable integrant containing five or fewer, and
desirably no episomal expression vectors, transcription is induced,
allowing dsRNA to be expressed in the cells. This method ensures
that, if desired, only one species or not more than about five
species of dsRNA is expressed per cell, as opposed to other methods
that express hundreds to thousands of double stranded species.
[0049] Another problem that can occur in other double stranded
expression systems or dsRNA delivery systems is that some dsRNA
sequences, possibly in certain cell types and through certain
delivery methods, may result in an interferon response (Jaramillo
et al., Cancer Invest. 13:327-338, 1995). During the induction of
post-transcriptional gene silencing events, induction of an
interferon response is not desired, as this could lead to cell
death and possibly to the prevention of gene silencing. An
additional advantage of the present invention is that the dsRNA
delivery methods described herein are performed such that an
interferon response is inhibited or prevented.
[0050] One of the components of an interferon response is the
induction of the interferon-induced protein kinase PKR (Jaramillo
et al., supra). Suppression of the interferon response and/or the
PKR response, using techniques described herein, is desired in the
cells targeted for a PTGS event in those instances where an
interferon response would otherwise be induced. Methods for
suppressing an interferon response or dsRNA stress response can be
used in combination with any of the methods for identifying a
nucleic acid sequence that modulates the function of a cell, gene
expression in a cell, or the biological activity of a target
polypeptide.
[0051] The methods of the present invention provide a means for
high throughput identification of nucleic acid sequences involved
in modulating the function of a cell, the expression of a target
nucleic acid in a cell, or the biological activity of a target
polypeptide in a cell. By transforming a population of cells with a
double stranded RNA expression library, the effects of many PTGS
events on cell function, expression of a target nucleic acid in a
cell, or the biological activity of a target polypeptide in a cell
can be evaluated simultaneously, thereby allowing for rapid
identification of the nucleic acid sequence involved in a cell
function, target nucleic acid expression, or biological activity of
a target polypeptide of interest.
[0052] By "nucleic acid," "nucleic acid sequence," "double stranded
RNA nucleic acid sequence," or "double stranded RNA nucleic acid"
is meant a nucleic acid or a portion thereof that is free of the
genes that, in the naturally-occurring genome of the organism from
which the nucleic acid sequence of the invention is derived, flank
the gene. The term therefore includes, for example, a recombinant
DNA, with or without 5' or 3' flanking sequences that is
incorporated into a vector, for example, a double stranded RNA
expression vector; into an autonomously replicating plasmid or
virus; or into the genomic DNA of a prokaryote or eukaryote; or
which exists as a separate molecule (e.g., a cDNA or a genomic or
cDNA fragment produced by PCR or restriction endonuclease
digestion) independent of other sequences.
[0053] By "double stranded RNA" is meant a nucleic acid containing
a region of two or more nucleotides that are in a double stranded
conformation. In various embodiments, the double stranded RNA
consists entirely of ribonucleotides or consists of a mixture of
ribonucleotides and deoxynucleotides, such as the RNA/DNA hybrids
disclosed, for example, by WO 00/63364, filed Apr. 19, 2000 or U.S.
Ser. No. 60/130,377, filed Apr. 21, 1999. The double stranded RNA
may be a single molecule with a region of self-complimentarity such
that nucleotides in one segment of the molecule base pair with
nucleotides in another segment of the molecule. In various
embodiments, a double stranded RNA that consists of a single
molecule consists entirely of ribonucleotides or includes a region
of ribonucleotides that is complimentary to a region of
deoxyribonucleotides. Alternatively, the double stranded RNA may
include two different strands that have a region of complimentarity
to each other. In various embodiments, both strands consist
entirely of ribonucleotides, one strand consists entirely of
ribonucleotides and one strand consists entirely of
deoxyribonucleotides, or one or both strands contain a mixture of
ribonucleotides and deoxyribonucleotides. Desirably, the regions of
complimentarity are at least 70, 80, 90, 95, 98, or 100%
complimentary. Desirably, the region of the double stranded RNA
that is present in a double stranded conformation includes at least
5, 10, 20, 30, 50, 75, 100, 200, 500, 1000, 2000 or 5000
nucleotides or includes all of the nucleotides in a cDNA being
represented in the double stranded RNA. In some embodiments, the
double stranded RNA does not contain any single stranded regions,
such as single stranded ends, or the double stranded RNA is a
hairpin. Desirable RNA/DNA hybrids include a DNA strand or region
that is an antisense strand or region (e.g., has at least 70, 80,
90, 95, 98, or 100% complimentary to a target nucleic acid) and an
RNA strand or region that is an sense strand or region (e.g., has
at least 70, 80, 90, 95, 98, or 100% identity to a target nucleic
acid). In various embodiments, the RNA/DNA hybrid is made in vitro
using enzymatic or chemical synthetic methods such as those
described herein or those described in WO 00/63364, filed Apr. 19,
2000 or U.S. Ser. No. 60/130,377, filed Apr. 21, 1999. In other
embodiments, a DNA strand synthesized in vitro is complexed with an
RNA strand made in vivo or in vitro before, after, or concurrent
with the transformation of the DNA strand into the cell. In yet
other embodiments, the double stranded RNA is a single circular
nucleic acid containing a sense and an antisense region, or the
double stranded RNA includes a circular nucleic acid and either a
second circular nucleic acid or a linear nucleic acid (see, for
example, WO 00/63364, filed Apr. 19, 2000 or U.S. Ser. No.
60/130,377, filed Apr. 21, 1999.) Exemplary circular nucleic acids
include lariat structures in which the free 5' phosphoryl group of
a nucleotide becomes linked to the 2' hydroxyl group of another
nucleotide in a loop back fashion.
[0054] In other embodiments, the double stranded RNA includes one
or more modified nucleotides in which the 2' position in the sugar
contains a halogen (such as flourine group) or contains an alkoxy
group (such as a methoxy group) which increases the half-life of
the double stranded RNA in vitro or in vivo compared to the
corresponding double stranded RNA in which the corresponding 2'
position contains a hydrogen or an hydroxyl group. In yet other
embodiments, the double stranded RNA includes one or more linkages
between adjacent nucleotides other than a naturally-occurring
phosphodiester linkage. Examples of such linkages include
phosphoramide, phosphorothioate, and phosphorodithioate linkages.
In other embodiments, the double stranded RNA contains one or two
capped strands, as disclosed, for example, by WO 00/63364, filed
Apr. 19, 2000 or U.S. Ser. No. 60/130,377, filed Apr. 21, 1999. In
other embodiments, the double stranded RNA contains coding sequence
or non-coding sequence, for example, a regulatory sequence (e.g., a
transcription factor binding site, a promoter, or a 5' or 3'
untranslated region (UTR) of an mRNA). Additionally, the double
stranded RNA can be any of the at least partially double-stranded
RNA molecules disclosed in WO 00/63364, filed Apr. 19, 2000 (see,
for example, pages 8-22). Any of the double stranded RNAs may be
expressed in vitro or in vivo using the methods described herein or
standard methods, such as those described in WO 00/63364, filed
Apr. 19, 2000 (see, for example, pages 16-22).
[0055] By "double stranded RNA expression library" or "dsRNA
expression library" is meant a collection of nucleic acid
expression vectors containing nucleic acid sequences, for example,
cDNA sequences or randomized nucleic acid sequences that are
capable of forming a double stranded RNA (dsRNA) upon expression of
the nucleic, acid sequence. Desirably the double stranded RNA
expression library contains at least 10,000 unique nucleic acid
sequences, more desirably at least 50,000; 100,000; or 500,000
unique nucleic acid sequences, and most desirably, at least
1,000,000 unique nucleic acid sequences. By a "unique nucleic acid
sequence" is meant that a nucleic acid sequence of a double
stranded RNA expression library has desirably less than 50%, more
desirably less than 25% or 20%, and most desirably less than 10%
nucleic acid identity to another nucleic acid sequence of a double
stranded RNA expression library when the full length sequence are
compared. Sequence identity is typically measured using sequence
analysis software with the default parameters specified therein
(e.g., Sequence Analysis Software Package of the Genetics Computer
Group, University of Wisconsin Biotechnology Center, 1710
University Avenue, Madison, Wis. 53705). This software program
matches similar sequences by assigning degrees of homology to
various substitutions, deletions, and other modifications.
[0056] The preparation of cDNAs for the generation of double
stranded RNA expression libraries is described herein. A randomized
nucleic acid library may also be generated as described in detail
below. The double stranded RNA expression library may contain
nucleic acid sequences that are transcribed in the nucleus or that
are transcribed in the cytoplasm of the cell. A double stranded RNA
expression library may be generated using techniques described
herein.
[0057] By "target nucleic acid" is meant a nucleic acid sequence
whose expression is modulated as a result of post-transcriptional
gene silencing. As used herein, the target nucleic acid may be in
the cell in which the PTGS event occurs or it may be in a
neighboring cell, or in a cell contacted with media or other
extracellular fluid in which the cell that has undergone the PTGS
event is contained. Exemplary target nucleic acids include nucleic
acids associated with cancer or abnormal cell growth, such as
oncogenes, and nucleic acids associated with an autosomal dominant
or recessive disorder. Desirably, the double stranded RNA inhibits
the expression of an allele of a nucleic acid that has a mutation
associated with a dominant disorder and does not substantially
inhibit the other allele of the nucleic acid (e.g., an allele
without a mutation associated with the disorder). Other exemplary
target nucleic acids include host cellular nucleic acids or
pathogen nucleic acids required for the infection or propagation of
a pathogen, such as a virus, bacteria, yeast, protozoa, or
parasite.
[0058] By "target polypeptide" is meant a polypeptide whose
biological activity is modulated as a result of
post-transcriptional gene silencing. As used herein, the target
polypeptide may be in the cell in which the PTGS event occurs or it
may be in a neighboring cell, or in a cell contacted with media or
other extracellular fluid in which the cell that has undergone the
PTGS event is contained.
[0059] As used herein, by "randomized nucleic acids" is meant
nucleic acids, for example, those that are at least 100, 500, 600,
or 1000 nucleotides in length, constructed from RNA isolated from a
particular cell type. In other embodiments, the nucleic acids are
at least 10, 20, 30, 40, 50, 60, 70, 80, or 90 nucleotides in
length. In yet other embodiments, the number of nucleotides in the
nucleic acids is between 5-100 nucleotides, 15-100 nucleotides,
20-95 nucleotides, 25-90 nucleotides, 35-85 nucleotides, 45-80
nucleotides, 50-75 nucleotides, or 55-70 nucleotides, inclusive. In
still other embodiments, the number of nucleotides in the nucleic
acids is contained in one of the following ranges: 5-15
nucleotides, 15-20 nucleotides, 20-25 nucleotides, 25-35
nucleotides, 35-45 nucleotides, 45-60 nucleotides, 60-70
nucleotides, 70-80 nucleotides, 80-90 nucleotides, or 90-100
nucleotides, inclusive. In other embodiments, the nucleic acids
contain less than 50,000; 10,000; 5,000; or 2,000 nucleotides. A
randomized nucleic acid library may be constructed in a number of
ways. For example, it may be constructed from existing cDNA
libraries. In one example, the cDNA libraries are shuffled using
the "Gene Shuffling" technology of Maxygen Corp. The cDNA sequences
are amplified using inefficient PCR either by restricting
elongation time or through the use of manganese. A library of
recombinants is created, and the library is finally amplified by
PCR and cloned into vectors. In a second method, existing cDNA
libraries are digested with an endonuclease to generate fragments
of 10 to 300 base pairs. Alternatively, the cDNA libraries are
digested to generate shorter fragments of, for example, 5 to 50
base pairs, 5 to 40 base pairs, 5 to 20 base pairs, 5 to 10 base
pairs, or 10 to 20 base pairs, inclusive. If the fragments are to
contain 5' OH and 3' PO.sub.4 groups, they are dephosphorylated
using alkaline phosphatase and phosphorylated using polynucleotide
kinase. These dsDNA fragments are then ligated to form larger
molecules, and are size selected. In a third example, randomized
nucleic acid libraries are created by using random priming of cDNA
libraries (using random hexamers and Klenow) to generate short
fragments of 20 to 100 nucleotides. Alternatively, shorter
fragments are generated that contain, for example, 5 to 50
nucleotides, 5 to 40 nucleotides, 5 to 20 nucleotides, 5 to 10
nucleotides, or 10 to 20 nucleotides, inclusive. These fragments
are then ligated randomly to give a desired sized larger
fragment.
[0060] Alternatively, a randomized nucleic acid library can be
generated from random sequences of oligonucleotides. For example,
DNA or RNA oligonucleotides may be prepared chemically. Random DNA
sequences may also be prepared enzymatically using terminal
transferase in the presence of all dNTPs. Random RNA molecules may
be prepared using NDPs and NDP phosphorylase. The random sequences
may be 10 to 300 bases in length. Alternatively, shorter random
sequences are used that contain, for example, 5 to 50 bases, 5 to
40 bases, 5 to 20 bases, 5 to 10 bases, or 10 to 20 bases,
inclusive. The sequences are ligated to form the desired larger
sequence using RNA ligase. Alternatively these sequences may be
ligated chemically. The oligonucleotides are phosphorylated at 6
the 5' position using polynucleotide kinase or by chemical methods,
prior to ligation enzymatically. Chemical ligations can utilize a
0.5' PO.sub.4 and a 3' OH group or a5' OH and a 3' PO.sub.4
group.
[0061] Alternatively, a randomized nucleic acid library can be
generated by converting the random DNA sequences into dsDNA
sequences using DNA polymerase (Klenow), dNTP and random
heteromeric primers, and the RNA sequences are converted into dsDNA
sequences by reverse transcriptase and Klenow. After converting
into DNA (ss or ds) the sequences are then amplified by PCR. The
dsDNA fragments can also be ligated to give larger fragments of a
desired size.
[0062] The randomized nucleic acids may be cloned into a vector,
for example, an expression vector, as a double stranded RNA
transcription cassette. The sequence of the nucleic acid may not be
known at the time the vector is generated. The randomized nucleic
acid may contain coding sequence or non-coding sequence, for
example, a regulatory sequence (e.g., a transcription factor
binding site, a promoter, or a 5' or 3' untranslated region (UTR)
of an mRNA).
[0063] By "Cre-mediated double recombination" is meant two nucleic
acid recombination events involving loxP sites that are mediated by
Cre recombinase. A Cre-mediated double recombination event can
occur, for example, as illustrated in FIG. 1.
[0064] By "function of a cell" is meant any cell activity that can
be measured or assessed. Examples of cell function include, but are
not limited to, cell motility, apoptosis, cell growth, cell
invasion, vascularization, cell cycle events, cell differentiation,
cell dedifferentiation, neuronal cell regeneration, and the ability
of a cell to support viral replication. The function of a cell may
also be to affect the function, gene expression, or the polypeptide
biological activity of another cell, for example, a neighboring
cell, a cell that is contacted with the cell, or a cell that is
contacted with media or other extracellular fluid that the cell is
contained in.
[0065] By "apoptosis" is meant a cell death pathway wherein a dying
cell displays a set of well-characterized biochemical hallmarks
that include cytolemmal membrane blebbing, cell soma shrinkage,
chromatin condensation, nuclear disintegration, and DNA laddering.
There are many well-known assays for determining the apoptotic
state of a cell, including, and not limited to: reduction of MTT
tetrazolium dye, TUNEL staining, Annexin V staining, propidium
iodide staining, DNA laddering, PARP cleavage, caspase activation,
and assessment of cellular and nuclear morphology. Any of these or
other known assays may be used in the methods of the invention to
determine whether a cell is undergoing apoptosis.
[0066] By "polypeptide biological activity" is meant the ability of
a target polypeptide to modulate cell function. The level of
polypeptide biological activity may be directly measured using
standard assays known in the art. For example, the relative level
of polypeptide biological activity may be assessed by measuring the
level of the mRNA that encodes the target polypeptide (e.g., by
reverse transcription-polymerase chain reaction (RT-PCR)
amplification or Northern blot analysis); the level of target
polypeptide (e.g., by ELISA or Western blot analysis); the activity
of a reporter gene under the transcriptional regulation of a target
polypeptide transcriptional regulatory region (e.g., by reporter
gene assay, as described below); the specific interaction of a
target polypeptide with another molecule, for example, a
polypeptide that is activated by the target polypeptide or that
inhibits the target polypeptide activity (e.g., by the two-hybrid
assay); or the phosphorylation or glycosylation state of the target
polypeptide. A compound, rid such as a dsRNA, that increases the
level of the target polypeptide, mRNA encoding the target
polypeptide, or reporter gene activity within a cell, a cell
extract, or other experimental sample is a compound that stimulates
or increases the biological activity of a target polypeptide. A
compound, such as a dsRNA, that decreases the level of the target
polypeptide, mRNA encoding the target polypeptide, or reporter gene
activity within a cell, a cell extract, or other experimental
sample is a compound that decreases the biological activity of a
target polypeptide.
[0067] By "assaying" is meant analyzing the effect of a treatment,
be it chemical or physical, administered to whole animals, cells,
tissues, or molecules derived therefrom. The material being
analyzed may be an animal, a cell, a tissue, a lysate or extract
derived from a cell, or a molecule derived from a cell. The
analysis may be, for example, for the purpose of detecting altered
cell function, altered gene expression, altered endogenous RNA
stability, altered polypeptide stability, altered polypeptide
levels, or altered polypeptide biological activity. The means for
analyzing may include, for example, antibody labeling,
immunoprecipitation, phosphorylation assays, glycosylation assays,
and methods known to those skilled in the art for detecting nucleic
acids. In some embodiments, assaying is conducted under selective
conditions.
[0068] By "modulates" is meant changing, either by a decrease or an
increase. As used herein, desirably a nucleic acid sequence
decreases the function of a cell, the expression of a target
nucleic acid in a cell, or the biological activity of a target
polypeptide in a cell by least 20%, more desirably by at least 30%,
40%, 50%, 60% or 75%, and most desirably by at least 90%. Also as
used herein, desirably a nucleic acid sequence increases the
function of a cell, the expression of a target nucleic acid in a
cell, or the biological activity of a target polypeptide in a cell
by at least 1.5-fold to 2-fold, more desirably by at least 3-fold,
and most desirably by at least 5-fold.
[0069] By "a decrease" is meant a lowering in the level of: a)
protein (e.g., as measured by ELISA or Western blot analysis); b)
reporter gene activity (e.g., as measured by reporter gene assay,
for example, .beta.-galactosidase, green fluorescent protein, or
luciferase activity); c) mRNA (e.g., as measured by RT-PCR or
Northern blot analysis relative to an internal control, such as a
"housekeeping" gene product, for example, J-actin or glyceraldehyde
3-phosphate dehydrogenase (GAPDH)); or d) cell function, for
example, as assayed by the number of apoptotic, mobile, growing,
cell cycle arrested, invasive, differentiated, or dedifferentiated
cells in a test sample. In all cases, the lowering is desirably by
at least 20%, more desirably by at least 30%, 40%, 50%, 60%, 75%,
and most desirably by at least 90%. As used herein, a decrease may
be the direct or indirect result of PTGS.
[0070] By "an increase" is meant a rise in the level of: a) protein
(e.g., as measured by ELISA or Western blot analysis); b) reporter
gene activity (e.g., as measured by reporter gene assay, for
example, .beta.-galactosidase, green fluorescent protein, or
luciferase activity); c) mRNA (e.g., as measured by RT-PCR or
Northern blot analysis relative to an internal control, such as a
"housekeeping" gene product, for example, .beta.-actin or
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)); or d) cell
function, for example, as assayed by the number of apoptotic,
mobile, growing, cell cycle arrested, invasive, differentiated, or
dedifferentiated cells in a test sample. Desirably, the increase is
by at least 1.5-fold to 2-fold, more desirably by at least 3-fold,
and most desirably by at least 5-fold. As used herein, an increase
may be the indirect result of PTGS. For example, the double
stranded RNA may inhibit the expression of a protein, such as a
suppressor protein, that would otherwise inhibit the expression of
another nucleic acid.
[0071] By "alteration in the level of gene expression" is meant a
change in transcription, translation, or mRNA or protein stability
such that the overall amount of a product of the gene, i.e., mRNA
or polypeptide, is increased or C decreased.
[0072] By "reporter gene" is meant any gene that encodes a product
whose expression is detectable and/or able to be quantitated by
immunological, chemical, biochemical, or biological assays. A
reporter gene product may, for example, have one of the following
attributes, without restriction: fluorescence (e.g., green
fluorescent protein), enzymatic activity (e.g.,
.beta.-galactosidase, luciferase, i) chloramphenicol
acetyltransferase), toxicity (e.g., ricin A), or an ability to be
specifically bound by an additional molecule (e.g., an unlabeled
antibody, followed by a labelled secondary antibody, or biotin, or
a detectably labelled antibody). It is understood that any
engineered variants of reporter genes that are readily available to
one skilled in the art, are also included, without restriction, in
the foregoing definition.
[0073] By "protein" or "polypeptide" or "polypeptide fragment" is
meant any chain of more than two amino acids, regardless of
post-translational modification (e.g., glycosylation or
phosphorylation), constituting all or part of a naturally-occurring
polypeptide or peptide, or constituting a non-naturally occurring
polypeptide or peptide.
[0074] By "promoter" is meant a minimal sequence sufficient to
direct transcription of a gene. Also included in this definition
are those transcription control elements (e.g., enhancers) that are
sufficient to render promoter-dependent gene expression
controllable in a cell type-specific, tissue-specific, or
temporal-specific manner, or that are inducible by external signals
or agents; such elements, which are well-known to skilled artisans,
may be found in a 5' or 3' region of a gene or within an intron.
Desirably a promoter is operably linked to a nucleic acid sequence,
for example, a cDNA or a gene in such a way as to permit expression
of the nucleic acid sequence.
[0075] By "operably linked" is meant that a gene and one or more
transcriptional regulatory sequences, e.g., a promoter or enhancer,
are connected in such a way as to permit gene expression when the
appropriate molecules (e.g., transcriptional activator proteins)
are bound to the regulatory sequences.
[0076] By "expression vector" is meant a DNA construct that
contains at least one promoter operably linked to a downstream gene
or coding region (e.g., a cDNA or genomic DNA fragment that encodes
a protein, optionally, operatively linked to sequence lying outside
a coding region, an antisense RNA coding region, or RNA sequences
lying outside a coding region). Transfection or transformation of
the expression vector into a recipient cell allows the cell to
express RNA encoded by the expression vector. An expression vector
may be a genetically engineered plasmid, virus, or artificial
chromosome derived from, for example, a bacteriophage, adenovirus,
retrovirus, poxvirus, or herpesvirus.
[0077] By "transformation" or "transfection" is meant any method
for introducing foreign molecules into a cell (e.g., a bacterial,
yeast, fungal, algal, plant, insect, or animal cell, particularly a
vertebrate or mammalian cell). The cell may be in an animal.
Lipofection, DEAE-dextran-mediated transfection, microinjection,
protoplast fusion, calcium phosphate precipitation, viral or
retroviral delivery; electroporation, and biolistic transformation
are just a few of the transformation/transfection methods known to
those skilled in the art. The RNA or RNA expression vector (DNA)
may be naked RNA or DNA or local anesthetic complexed RNA or DNA
(Pachuk et al., supra). Other standard transformation/transfection
methods and other RNA and/or DNA delivery agents (e.g., a cationic
lipid, liposome, or bupivacaine) are described in WO 00/63364,
filed Apr. 19, 2000 (see, for example, pages 18-26). Commercially
available kits can also be used to deliver RNA or DNA to a cell.
For example, the Transmessenger Kit from Qiagen, an RNA kit from
Xeragon Inc., and an RNA kit from DNA Engine Inc. (Seattle, Wash.)
can be used to introduce single or double stranded RNA into a
cell.
[0078] By "transformed cell" or "transfected cell" is meant a cell
(or a descendent of a cell) into which a nucleic acid molecule, for
example, a double stranded RNA or double stranded expression vector
has been introduced, by means of recombinant nucleic acid
techniques. Such cells may be either stably or transiently
transfected.
[0079] By "selective conditions" is meant conditions under which a
specific cell or group of cells can be selected for. For example,
the parameters of a fluorescence-activated cell sorter (FACS) can
be modulated to identify a specific cell or group of cells. Cell
panning, a technique known to those skilled in the art, is another
method that employs selective conditions.
[0080] As use herein, by "optimized" is meant that a nucleic acid
fragment is generated through inefficient first strand synthesis
(e.g., reverse transcription (RT) and/or RT/second strand synthesis
(RT-SSS) using Klenow or other enzymes and/or RT-PCR or PCR, to be
of a particular length. Desirably the length of the nucleic acid
fragment is less than a full length cDNA or is 100, 500, 600, or
1000 nucleotides in length. In other embodiments, the nucleic acid
fragment is at least 10, 20, 30, 40, 50, 60, 70, 80, or 90
nucleotides in length. In yet other embodiments, the number of
nucleotides in the nucleic acid fragment is between 5-100
nucleotides, 15-100 nucleotides, 20-95 nucleotides, 25-90
nucleotides, 35-85 nucleotides, 45-80 nucleotides, 50-75
nucleotides, or 55-70 nucleotides, inclusive. In still other
embodiments, the number of nucleotides in the nucleic acid fragment
is contained in one of the following ranges: 5-15 nucleotides,
15-20 nucleotides, 20-25 nucleotides, 25-35 nucleotides, 35-45
nucleotides, 45-60 nucleotides, 60-70 nucleotides, 70-80
nucleotides, 80-90 nucleotides, or 90-100 nucleotides, inclusive.
In other embodiments, the nucleic acid fragment contains less than
50,000; 10,000; 5,000; or 2,000 nucleotides. Optimization of the
length of a nucleic acid can be achieved during first strand or
second strand synthesis of a desired nucleic acid by lowering
Mg.sup.++ concentrations to no less than the nucleotide
concentrations; by adding Mn.sup.++ to the reaction to achieve the
desired size selection (e.g., by replacing Mg.sup.++ completely, or
by adding Mn.sup.++ at varying concentrations along with
Mg.sup.++); by decreasing and/or limiting concentrations of dNTP(s)
to effect the desired fragment size; by using various
concentrations of ddNTP(s) along with standard or optimal
concentrations of dNTP(s), to achieve varying ratios, to obtain the
desired fragment size; by using limited and controlled exonuclease
digestion of the fragment following RT, RT-SSS, RT-PCR, or PCR; or
by a combination of any of these methods.
[0081] As used herein, by "sized selected" is meant that a nucleic
acid of a particular size is selected for use in the construction
of dsRNA expression libraries as described herein. Desirably the
size selected nucleic acid is less than a full length cDNA sequence
or at least 100, 500, 600, or 1000 nucleotides in length. In other
embodiments, the nucleic acid is at least 10, 20, 30, 40, 50, 60,
70, 80, or 90 nucleotides in length. In yet other embodiments, the
number of nucleotides in the nucleic acid is between 5-100
nucleotides, 15-100 nucleotides, 20-95 nucleotides, 25-90
nucleotides, 35-85 nucleotides, 45-80 nucleotides, 50-75
nucleotides, or 55-70 nucleotides, inclusive. In still other
embodiments, the number of nucleotides in the nucleic acid is
contained in one of the following ranges: 5-15 nucleotides,
15-nucleotides, 20-25 nucleotides, 25-35 nucleotides, 35-45
nucleotides, 45-60 nucleotides, 60-70 nucleotides, 70-80
nucleotides, 80-90 nucleotides, or 90-100 nucleotides, inclusive.
In other embodiments, the nucleic acid contains less than 50,000;
10,000; 5,000; or 2,000 nucleotides. For example, a nucleic acid
may be size selected using size exclusion chromatography (e.g., as
size exclusion Sepharose matrices) according to standard procedures
(see, for example, Sambrook, Fritsch, and Maniatis, Molecular
Cloning: A Laboratory Manual (2d ed.), Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y., 1989).
[0082] By "under conditions that inhibit or prevent an interferon
response or a dsRNA stress response" is, meant conditions that
prevent or inhibit one or more interferon responses or cellular RNA
stress responses involving cell toxicity, cell death, an
anti-proliferative response, or a decreased ability of a dsRNA to
carry out a PTGS event. These responses include, but are not
limited to, interferon induction (both Type 1 and Type II),
induction of one or more interferon stimulated genes, PKR
activation, 2'5'-OAS activation, and any downstream cellular and/or
organismal sequelae that result from the activation/induction of
one or more of these responses. By "organismal sequelae" is meant
any effect(s) in a whole animal, organ, or more locally (e.g., at a
site of injection) caused by the stress response. Exemplary
manifestations include elevated cytokine production, local
inflammation, and necrosis. Desirably the conditions that inhibit
these responses are such that not more than 95%, 90%, 80%, 75%,
60%, 40%, or 25%, and most desirably not more than 10% of the cells
undergo cell toxicity, cell death, or a decreased ability to carry
out a PTGS event, compared to a cell not exposed to such interferon
response inhibiting conditions, all other conditions being equal
(e.g., same cell type, same transformation with the same dsRNA
expression library.
[0083] Apoptosis, interferon induction, 2'5' OAS
activation/induction, PKR induction/activation, anti-proliferative
responses, and cytopathic effects are all indicators for the RNA
stress response pathway. Exemplary assays that can be used to
measure the induction of an RNA stress response as described herein
include a TUNEL assay to detect apoptotic cells, ELISA assays to
detect the induction of alpha, beta and gamma interferon, ribosomal
RNA fragmentation analysis to detect activation of 2' 5'OAS,
measurement of phosphorylated eIF2a as an indicator of PKR (protein
kinase RNA inducible) activation, proliferation assays to detect
changes in cellular proliferation, and microscopic analysis of
cells to identify cellular cytopathic effects (see, e.g., Example
11). Desirably, the level of an interferon response or a dsRNA
stress response in a cell transformed with a double stranded RNA or
a double stranded RNA expression vector is less than 20, 10, 5, or
2-fold greater than the corresponding level in a mock-transfected
control cell under the same conditions, as measured using one of
the assays described herein. In other embodiments, the level of an
interferon response or a dsRNA stress response in a cell
transformed with a double stranded RNA or a double stranded RNA
expression vector using the methods of the present invention is
less than 500%, 200%, 100%, 50%, 25%, or 10% greater than the
corresponding level in a corresponding transformed cell that is not
exposed to such interferon response inhibiting conditions, all
other conditions being equal. Desirably, the double stranded RNA
does not induce a global inhibition of cellular transcription or
translation.
[0084] By "specifically hybridizes" is meant a double stranded RNA
that hybridizes to a target nucleic acid but does not substantially
hybridize to other nucleic acids in a sample (e.g., a sample from a
cell) that naturally includes the target nucleic acid, when assayed
under denaturing conditions. In one embodiment, the amount of a
target nucleic acid hybridized to, or associated with, the double
stranded RNA, as measured using standard assays, is 2-fold,
desirably 5-fold, more desirably 10-fold, and most desirably
50-fold greater than the amount of a control nucleic acid
hybridized to, or associated with, the double stranded RNA.
[0085] By "high stringency conditions" is meant hybridization in
2.times.SSC at 40.degree. C. with a DNA probe length of at least 40
nucleotides. For other definitions of high stringency conditions,
see F. Ausubel et al., Current Protocols in Molecular Biology, pp.
6.3.1-6.3.6, John Wiley & Sons, New York, N.Y., 1994, hereby
incorporated by reference.
[0086] Conditions and techniques that can be used to prevent an
interferon response or dsRNA stress response during the screening
methods of the present invention are described herein.
BRIEF DESCRIPTION OF THE DRAWING
[0087] FIG. 1 is a schematic representation of a strategy to
isolate clonally pure stable integrants that contain a single
expression unit isolated from cells transfected with a
double-stranded RNA encoding a cDNA library.
[0088] FIG. 2 is a schematic illustration of the production of
effector RNAs in cells expressing PSA. The PSA expression cassette
used to create the transient PSA expression cell line is depicted
at the top of the figure. Expression of PSA is nrl driven by the
HCMV IE promoter and the SV40 polyadenylation signal (pA). Only
sequences 3' of the PSA initiation codon have been used in these
vectors. The effector RNA expression cassettes are shown below the
PSA expression cassette and are designed to express PSA sense RNA,
PSA antisense RNA, and PSA dsRNA. Expression of the effector RNAs
is under the control of the T7 promoter (T7p). Transcription from
T7p is catalyzed by T7 RNA polymerase, which is supplied by
co-transfecting a T7 RNA polymerase expression plasmid (not shown).
Control effector RNA cassettes expressing irrelevant RNAs derived
from the Herpes simplex virus glycoprotein D gene were included as
controls. The 600 base pair sequence from the Herpes simplex gD
gene is from Herpes Simplex virus 2 strain 12 and maps to the
coding region downstream of the gD initiation codon.
[0089] FIG. 3 is a bar graph illustrating silencing of PSA
expression by dsRNA. PSA levels in the supernates of transfected
cells were determined by ELISA and are plotted as percent
expression of the PSA untreated control. The PSA untreated control
shown at the left is normalized to 100%. PSA levels in the
supernates of cells transfected with the various effector PSA or
control RNAs are shown by the shaded and open bars respectively.
All data shown is from day two post-transfection. Data from later
time points were similar to the day two time point.
[0090] FIG. 4 is a schematic illustration of the RNA stress
response pathway, also known as the Type 1 interferon response.
DETAILED DESCRIPTION OF THE INVENTION
[0091] Post-transcriptional gene silencing (PTGS) can be used as a
tool to identify and validate specific unknown genes involved in
cell function, gene expression, and polypeptide biological
activity. Although the use of PTGS as a validation strategy is well
documented in invertebrates and plants, its use in identification
of genes that modulate cell function, gene expression, or
polypeptide biological activity, as described below, is novel.
Since novel genes are likely to be identified through the methods
of the present invention, PTGS is developed for use in validation
and to identify novel targets for use in therapies for diseases,
for example, cancer, neurological disorders, obesity, leukemia,
lymphomas, and other disorders of the blood or immune system.
[0092] The present invention features methods to identify unknown
targets that result in the modulation of a particular phenotype, an
alteration of gene expression in a cell, or an alteration in
polypeptide biological activity in a cell, using either a library
based screening approach or a non-library based approach to
identify nucleic acids that induce gene silencing. The present
invention also allows the determination of function of a given
sequence. These methods involve the direct delivery of in vitro
transcribed double stranded RNA (dsRNA), as well as plasmid-based
systems that direct the cell to make its own dsRNA. To avoid
problems associated with transfection efficiency, plasmids are
designed to contain a selectable marker to ensure the survival of
only those cells that have taken up plasmid DNA. One group of
plasmids directs the synthesis of dsRNA that is transcribed in the
cytoplasm, while another group directs the synthesis of dsRNA that
is transcribed in the nucleus.
Identification of Genes by Assaying for a Modulation in Cell
Function
[0093] Functional identification of novel genes can be accomplished
through the use of a number of different assays. For example, cells
may be assayed for cell motility, apoptosis, cell growth, cell
invasion, vascularization, cell cycle events, cell differentiation,
cell dedifferentiation, neuronal cell regeneration, or the ability
to support viral replication, as well as other cell functions known
in the art. Methods for carrying out such functional assays are
well known and are described, for example, in Platet and Garcia
(Invasion Metastasis 18:198-208, 1998-1999); Harper et al.
(Neuroscience 88:257-267, 1999); and Tomaselli et al. (J. Cell
Biol. 105:2347-2358, 1987), and are also described below.
[0094] Functional identification of nucleic acid sequences involved
in modulating a particular cell function may be carried out by
comparing cells transfected with a dsRNA to control cells that have
not been transformed with a dsRNA or that have been
mock-transfected, in a functional assay. A cell that has taken up
sequences unrelated to a particular function will perform in the
particular assay in a manner similar to the control cell. A cell
experiencing PTGS of a gene involved in the particular function
will exhibit an altered ability to perform in the functional assay
compared to the control.
[0095] The percent modulation of a particular cell function that
identifies a nucleic acid sequence that modulates the function of a
cell will vary depending on the assay, phenotype, and the
particular nucleic acid affected by PTGS. For each assay, the
percent modulation can readily be determined by one skilled in the
art, when used in conjunction with controls, as described herein.
Desirably the modulation is at least 20%, more desirably at least
30%, 40%, 50%, 60%, 75%, and most desirably at least 90% compared
to the control. An increase in the function of a cell can also be
measured in terms of fold increase, where desirably, the increase
is at least 1.5-fold to 5-fold compared to the control.
[0096] Alternatively, the function of a cell may be to affect the
function, gene expression, or polypeptide biological activity of
another cell, for example, a neighboring cell, a cell that is
contacted with the cell in which a PTGS event occurs, or a cell
that is contacted with media or other extracellular fluid that the
cell in which a PTGS event occurs is contained in. For example, a
cell experiencing PTGS of a gene may modulate cell motility,
apoptosis, cell growth, cell invasion, vascularization, cell cycle
events, cell differentiation, cell dedifferentiation, neuronal cell
regeneration, or the ability to support viral replication of a
nearby cell, or a cell that is exposed to media or other
extracellular fluid in which the transfected cell in which a PTGS
event occurs was once contained. This can be tested by removing the
media in which a cell experiencing a PTGS event is occurring and
placing it on a separate cell or population of cells. If the
function of the separate cell or population of cells is modulated,
compared to a cell or population of cells receiving media obtained
from cells that had been mock transfected, then one or more of the
cells experiencing a PTGS event can affect the function of another
cell. The identity of the nucleic acid sequence that causes the
modulation can be identified with repeated rounds of selection.
[0097] In another method, a single cell experiencing a PTGS event
can be placed in proximity of a cell or a population of cells that
was not transfected with dsRNA, and the effect of this placement is
evaluated for a modulation in the function of the cell or
population of cells. If the function of the non-transfected cell or
population of cells is modulated, compared to a cell or population
of cells in proximity of a cell that was mock transfected, then the
cell experiencing a PTGS event contains a nucleic acid sequence
that can affect the function of another cell. This nucleic acid
sequence can be identified using techniques described herein.
Identification of Genes Using Differential Gene Expression
[0098] Differential gene expression analysis can be used to
identify a nucleic acid sequence that modulates the expression of a
target nucleic acid in a cell. Alterations in gene expression
induced by gene silencing can be monitored in a cell into which a
dsRNA has been introduced. For example, differential gene
expression can be assayed by comparing nucleic acids expressed in
cells into which dsRNA has been introduced to nucleic acids
expressed in control cells that were not transfected with dsRNA or
that were mock-transfected. Gene array technology can be used in
order to simultaneously examine the expression levels of many
different nucleic acids. Examples of methods for such expression
analysis are described by Marrack et al. (Current Opinions in
Immunology 12:206-209, 2000); Harkin (Oncologist 5:501-507, 2000);
Pelizzari et al. (Nucleic Acids Res. 28:4577-4581, 2000); and Marx
(Science 289:1670-1672, 2000).
Identification of Genes by Assaying Polypeptide Biological
Activity
[0099] Novel nucleic acid sequences that modulate the biological
activity of a target polypeptide can also be identified by
examining polypeptide biological activity. Various polypeptide
biological activities can be evaluated to identify novel genes
according to the methods of the invention. For example, the
expression of a target polypeptide(s) may be examined.
Alternatively, the interaction between a target polypeptide(s) and
another molecule(s), for example, another polypeptide or a nucleic
acid may be assayed. Phosphorylation or glycosylation of a target
polypeptide(s) may also be assessed, using standard methods known
to those skilled in the art.
[0100] Identification of nucleic acid sequences involved in
modulating the biological activity of a target polypeptide may be
carried out by comparing the polypeptide biological activity of a
cell transfected with a dsRNA to a control cell that has not been
transfected with a dsRNA or that has been mock-transfected. A cell
that has taken up sequences unrelated to a particular polypeptide
biological activity will perform in the particular assay in a
manner similar to the control cell. A cell experiencing PTGS of a
gene involved in the particular polypeptide biological activity
will exhibit an altered ability to perform in the biological assay,
compared to the control.
Insertion of Single Units into the Chromosome and Generation of a
Cell Line Containing a Single dsRNA Expression Library
Integrant
[0101] The present invention involves the generation of a target
cell line in which the dsRNA expression library is subsequently
introduced. Through the use of site-specific recombination, single
integrants of dsRNA expression cassettes are generated at the same
locus of all cells in the target cell line, allowing uniform
expression of the dsRNA in all of the integrants. A dsRNA
expression library derived from various cell lines is used to
create a representative library of stably integrated cells, each
cell within the target cell line containing a single integrant.
Cre/lox, Lambda-Cro repressor, and Flp recombinase systems or
retroviruses are used to generate these singular integrants of
dsRNA expression cassettes in the target cell line (Satoh et al.,
J. Virol. 74:10631-10638, 2000; Trinh et al., J. Immunol. Methods
244:185-193, 2000; Serov et al., An. Acad. Bras. Cienc. 72:389-398,
2000; Grez et al., Stem Cells. 16:235-243, 1998; Habu et al.,
Nucleic Acids Symp. Ser. 42:295-296, 1999; Haren et al., Annu. Rev.
Microbiol. 53:245-281, 1999; Baer et al., Biochemistry
39:7041-7049, 2000; Follenzi et al., Nat. Genet. 25:217-222, 2000;
Hindmarsh et al., Microbiol. Mol. Biol. Rev. 63:836-843, 1999;
Darquet et al., Gene Ther. 6:209-218, 1999; Darquet et al., Gene
Ther. 6:209-218, 1999; Yu et al., Gene 223:77-81, 1998; Darquet et
al., Gene Ther. 4:1341-1349, 1997; and Koch et al., Gene
249:135-144, 2000). These systems are used singularly to generate
singular insertion clones, and also in combination.
[0102] The following exemplary sequence specific integrative
systems use short target sequences that allow targeted
recombination to be achieved using specific proteins: FLP
recombinase, bacteriophage Lambda integrase, HIV integrase, and
pilin recombinase of Salmonella (Seng et al. Construction of a Flp
"exchange cassette" contained vector and gene targeting in mouse ES
cell] A book chapter PUBMED entry 11797223--Sheng Wu Gong Cheng Xue
Bao. 2001 September; 17(5):566-9, Liu et al., Nat Genet. 2001 Jan.
1; 30(1):66-72, Awatramani et al., Nat Genet. 2001 November;
29(3):257-9, Heidmann and Lehner, Dev Genes Evol. 2001 September;
211(8-9):458-65, Schaft et al., Genesis. 2001 September;
31(1):6-10, Van Duyne, Annu Rev Biophys Biomol Struct. 2001; 30:
87-104, Lorbach et al., J Mol Biol. 2000 Mar. 10; 296(5):1175-81,
Darquet et al., Gene Ther. 1999 February; 6(2):209-18, Bushman and
Miller, J Virol. 1997 January; 71(1):458-64, Fulks et al., J
Bacteriol. 1990 January; 172(1):310-6). A singular integrant is
produced by randomly inserting the specific sequence (e.g., loxP in
the cre recombinase system) and selecting or identifying the cell
that contains a singular integrant that supports maximal
expression. For example, integrants that show maximal expression
following random integration can be identified through the use of
reporter gene sequences associated with the integrated sequence.
The cell can be used to specifically insert the expression cassette
into the site that contains the target sequence using the specific
recombinase, and possibly also remove the expression cassette that
was originally placed to identify the maximally expressing
chromosomal location. A skilled artisan can also produce singular
integrants using retroviral vectors, which integrate randomly and
singularly into the eukaryotic genome. In particular, singular
integrants can be produced by inserting retroviral vectors that
have been engineered to contain the desired expression cassette
into a naive cell and selecting for the chromosomal location that
results in maximal expression (Michael et al., EMBO Journal, vol
20: pages 2224-2235, 2001; Reik and Murrell., Nature, vol. 405,
page 408-409, 2000; Berger et al., Molecular Cell, vol. 8, pages
263-268). One may also produce a singular integrant by
cotransfecting the bacterial RecA protein with or without nuclear
localization signal along with sequences that are homologous to the
target sequence (e.g., a target endogenous sequence or integrated
transgene sequence). Alternatively, a nucleic acid sequence that
encodes a RecA protein with nuclear localization signals can be
cotransfected (Shibata et al., Proc Natl Acad Sci USA. 2001 Jul.
17; 98(15):8425-32. Review, Muyrers et al., Trends Biochem Sci.
2001 May; 26(5):325-31, Paul et al., Mutat Res. 2001 Jun. 5;
486(1):11-9, Shcherbakova et al., Mutat Res. 2000 Feb. 16;
459(1):65-71, Lantsov. Mol Biol (Mosk). 1994 May-June;
28(3):485-95).
[0103] An example utilizing such methods is detailed below.
[0104] Creation of the Target Cell Line
[0105] Target cell lines are the same cell lines as the ones from
which the dsRNA expression libraries will be derived. Target cells
are created by transfecting the selected cell line with a
bicistronic plasmid expressing a selectable marker, such as G418
and the reporter gene GFP. The plasmid also bears a loxP site.
Plasmids integrate randomly into the chromosome through the process
of illegitimate recombination at a frequency of 10.sup.-4.
Following transfection, cells containing integrants are selected by
culturing the cells in the presence of G418 at a concentration
determined earlier in a kill curve analysis. About a dozen
G418-resistant colonies are expanded and relative GFP expression
levels are determined using flow cytometry. DNA from the cells is
analyzed by Southern blot analysis to determine integrant copy
number. Several single copy integrants exhibiting the highest GFP
expression levels are then selected as the target cell lines. GFP
expression is monitored because dsRNA encoding templates are then
integrated into the loci containing the loxP, GFP, and G418
cassettes in a site-specific fashion, and it is important to ensure
that these loci are transcriptionally active. Since cells are
selected on the basis of G418 resistance and GFP expression,
integration of the plasmid DNA can occur at the loxP site,
destroying its function. Several cell lines are therefore chosen to
reasonably ensure that at least one integrant has an intact loxP
site.
[0106] Double Stranded RNA Expression Library Construction and
Site-Specific Recombination into the Target Cell Line
[0107] A cDNA library or a randomized library is constructed from
RNA isolated Pd from selected cell lines. cDNAs or randomized
nucleic acids in the size range of at least 100 to 1000
nucleotides, for example, 500 to 600 nucleotides are optimized
during synthesis or are size-selected prior to cloning. In other
embodiments, the nucleic acids are at least 10, 20, 30, 40, 50, 60,
70, 80, or 90 nucleotides in length. In yet other embodiments, the
number of nucleotides in the nucleic acids is between 5-100
nucleotides, 15-100 nucleotides, 20-95 nucleotides, 25-90
nucleotides, 35-85 nucleotides, 45-80 nucleotides, 50-75
nucleotides, or 55-70 nucleotides, inclusive. In still other
embodiments, the number of nucleotides in the nucleic acids is
contained in one of the following ranges: 5-15 nucleotides, 15-20
nucleotides, 20-25 nucleotides, 25-35 nucleotides, 35-45
nucleotides, 45-60 nucleotides, 60-70 nucleotides, 70-80
nucleotides, 80-90 nucleotides, or 90-100 nucleotides, inclusive.
In other embodiments, the nucleic acid contains less than 50,000;
10,000; 5,000; or 2,000 nucleotides. Each cDNA or randomized
nucleic acid is then cloned into a plasmid vector as a dsRNA
transcription cassette flanked by two convergent promoters (such as
T7 promoters as described herein). The promoters are
transcriptionally regulated such that they are off until induced,
for example, using a tet ON/OFF system (Forster et al., Nucleic
Acids Res. 27:7708-710, 1999; Liu et al., Biotechniques 24:624-628,
6, 30-632, 1998; and Gatz, Methods Cell Biol. 50:411-424, 1995).
The plasmid also contains the hygromycin resistance gene and an
inverted loxP site. The cDNA plasmid library or randomized plasmid
library is then co-transfected into the target cell line with a
plasmid expressing Cre recombinase, which catalyzes site-specific
recombination of the transfected cDNA plasmid or randomized nucleic
acid plasmid at the inverted loxP site into the chromosomal locus
containing the GFP gene and loxP site (see FIG. 1). The use of the
Cre/lox system allows the efficient integration of a plasmid into
the chromosome (every transfected cell is predicted to undergo a
plasmid integration event). Other site-specific recombination
strategies can also be utilized. This results in having every
integration to occur at the same site, thereby obviating potential
problems with loci dependent expression.
[0108] Two days following transfection, cells are incubated in the
presence of hygromycin to kill untransfected cells and to select
for stable integrants. Transcription of dsRNA is induced, and
selected cells are assayed for an alteration in cell function, the
biological activity of a target polypeptide, or differential gene
expression. Cells expressing dsRNA corresponding to a target
nucleic acid exhibit an altered function, for example, increased or
decreased cell invasion, motility, apoptosis, growth,
differentiation, dedifferentiation, or regeneration, or the ability
of the cell to support viral replication. Cells exhibiting altered
function are then expanded and the sequence of the integrant is
determined. Targets are identified and validated using dsRNA
specific for the identified target, or other non-PTGS mediated
methods, for example antisense technology.
[0109] The regulated transcription system of the present invention
provides an advantage to other double stranded expression systems.
Following transfection of the dsRNA library, cells contain hundreds
to thousands of dsRNA expression cassettes, with concomitant
expression of that many expression cassettes. In the dsRNA
expression system of the present invention, dsRNA expression
cassettes contained within the expression vector integrate into the
chromosome of the transfected cell. As described in detail below,
every transfected cell integrates one of the double stranded
expression cassettes. Desirably no transcription occurs until the
episomal (non-integrated) expression vectors are diluted out of the
cell such that not more than 5 episomal vectors remain in the cell.
Most desirably no transcription occurs until all of the episomal
(non-integrated) expression vectors are diluted out of the cell and
only the integrated expression cassette remains (a process usually
taking about two to several weeks of cell culture). At this time
transcription is induced, allowing dsRNA to be expressed in the
cells. This method ensures that only one species of dsRNA is
expressed per cell, as opposed to other methods that express
hundreds to thousands of double stranded species. The use of the
above-described system results in the loss of all but one
expression cassette, which in turn, permits the rapid screening of
libraries without requiring screening multiple pools of libraries
to identify the target gene.
Non-Library Approaches for the Identification of a Nucleic Acid
Sequence that Modulates Cell Function, Gene Expression in a Cell,
or the Biological Activity of a Target Polypeptide in a Cell
Through PTGS
[0110] Nucleic acid sequences that modulate cell function, gene
expression in a cell, or the biological activity of a target
polypeptide in a cell may also be identified using non-library
based approaches involving PTGS. For example, a single known
nucleic acid sequence encoding a polypeptide with unknown function
or a single nucleic acid fragment of unknown sequence and/or
function can be made into a double stranded RNA molecule. This
dsRNA is then transfected into a desired cell type and the cell is
assayed for modulations in cell function, gene expression of a
target nucleic acid in the cell, or the biological activity of a
target polypeptide in the cell, using methods described herein. A
modulation in cell function, gene expression in the cell, or the
biological activity of a target polypeptide in the cell identifies
the nucleic acid of the dsRNA as a nucleic acid the modulates the
specific cell function, gene expression, or the biological activity
of a target polypeptide. As a single dsRNA species is transfected
into the cells, the nucleic acid sequence responsible for the
modulation is readily identified. This non-library based approach
to nucleic acid identification is desirably used under conditions
that inhibit an interferon response or dsRNA stress response. Such
conditions are described in detail herein.
[0111] The discovery of novel genes through the methods of the
present invention may lead to the generation of novel therapeutics.
For example, genes that decrease cell invasion may be used as
targets for drug development, such as for the development of
cytostatic therapeutics for use in the treatment of cancer.
Development of such therapeutics is important because currently
available cytotoxic anticancer agents are also toxic for normal
rapidly dividing cells. In contrast, a cytostatic agent may only
need to check metastatic processes, and by inference, slow cell
growth, in order to stabilize the disease. In another example,
genes that increase neuronal regeneration may be used to develop
therapeutics for the treatment, prevention, or control of a number
of neurological diseases, including Alzheimer's disease and
Parkinson's disease. Genes that are involved in the ability to
support viral replication and be used as targets in anti-viral
therapies. Such therapies may be used to treat, prevent, or control
viral diseases involving human immunodeficiency virus (HIV),
hepatitis C virus (HCV), hepatitis B virus (HBV), and human
papillomavirus (HPV). The efficacies of therapeutics targeting the
genes identified according to the present invention can be further
tested in cell culture assays, as well as in animal models.
The Use of Vertebrate or Mammalian Cell Lines for Identification of
Nucleic Acid Sequences that Modulate Cell Function, Expression of a
Target Nucleic Acid, or Biological Activity of a Target
Polypeptide
[0112] While the use of the present invention is not limited to
vertebrate or mammalian cells, such cells can be used to carry out
the nucleic acid identification methods described herein. Desirably
the vertebrate or mammalian cells used to carry out the present
invention are cells that have been cultured for only a small number
of passages (e.g., less than 30 passages of a cell line that has
been obtained directly from American Type Culture Collection), or
are primary cells. In addition, vertebrate or mammalian cells can
be used to carry out the present invention when the dsRNA being
transfected into the cell is not complexed with cationic
lipids.
[0113] The following examples are to illustrate the invention. They
are not meant to limit the invention in any way. For example, it is
noted that any of the following examples can be used with double
stranded RNAs of any length. The methods of the present invention
can be readily adapted by one skilled in the art to utilize double
stranded RNAs of any desired length.
Example 1
Design and Delivery of Vectors for Intracellular Synthesis of dsRNA
for Library Based Screening Approaches to Nucleic Acid
Identification Using PTGS
[0114] PTGS is induced when dsRNA is made intracellularly. The
library based screening approaches to nucleic acid identification
through PTGS may require that dsRNA reside in certain cellular
compartments in order to exert its effect. Therefore, expression
plasmids that transcribe dsRNA in the cytoplasm and in the nucleus
are utilized. There are two classes of nuclear transcription
vectors: one that is designed to express polyadenylated dsRNA (for
example, a vector containing an RNA polymerase II promoter and a
poly A site) and one that expresses non-adenylated dsRNA (for
example, a vector containing an RNA polymerase II promoter and no
poly A site, or a vector containing a T7 promoter). Different
cellular distributions are predicted for the two species of RNA;
both vectors are transcribed in the nucleus, but the ultimate
destinations of the RNA species are different intracellular
locations. Intracellular transcription may also utilize
bacteriophage T7 and SP6 RNA polymerase, which may be designed to
transcribe in the cytoplasm or in the nucleus. Alternatively, Qbeta
replicase RNA-dependent RNA polymerase may be used to amplify
dsRNA. Viral RNA polymerases, either DNA and RNA dependent, may
also be used. Alternatively, dsRNA replicating polymerases can be
used. Cellular polymerases such as RNA Polymerase I, II, or III or
mitochondrial RNA polymerase may also be utilized. Both the
cytoplasmic and nuclear transcription vectors contain an antibiotic
resistance gene to enable selection of cells that have taken up the
plasmid. Cloning strategies employ chain reaction cloning (CRC), a
one-step method for directional ligation of multiple fragments
(Pachuk et al., Gene 243:19-25, 2000). Briefly, the ligations
utilize bridge oligonucleotides to align the DNA fragments in a
particular order and ligation is catalyzed by a heat-stable DNA
ligase, such as Ampligase, available from Epicentre.
[0115] Inducible or Repressible Transcription Vectors for the
Generation of a dsRNA Expression Library
[0116] If desired, inducible and repressible transcription systems
can be used to control the timing of the synthesis of dsRNA.
Inducible and repressible regulatory systems involve the use of
promoter elements that contain sequences that bind prokaryotic or
eukaryotic transcription factors upstream of the sequence encoding
dsRNA. In addition, these factors also carry protein domains that
transactivate or transrepress the RNA polymerase II. The regulatory
system also has the ability to bind a small molecule (e.g., a
coinducer or a corepressor). The binding of the small molecule to
the regulatory protein molecule (e.g., a transcription factor)
results in either increased or decreased affinity for the sequence
element. Both inducible and repressible systems can be developed
using any of the inducer/transcription factor combinations by
positioning the binding site appropriately with respect to the
promoter sequence. Examples of previously described
inducible/repressible systems include lacI, ara, Steroid-RU486, and
ecdysone--Rheogene, Lac (Cronin et al. Genes & Development 15:
1506-1517, 2001), ara (Khlebnikov et al., J Bacteriol. 2000
December; 182(24):7029-34), ecdysone (Rheogene, www.rheogene.com),
RU48 (steroid, Wang X J, Liefer K M, Tsai S, O'Malley B W, Roop D
R., Proc Natl Acad Sci USA. 1999 Jul. 20; 96(15):8483-8), tet
promoter (Rendal et al., Hum Gene Ther. 2002 January; 13(2):335-42,
and Larnartina et al., Hum Gene Ther. 2002 January; 13(2):199-210),
or a promoter disclosed in WO 00/63364, filed Apr. 19, 2000.
[0117] Nuclear Transcription Vectors for the Generation of a
Nuclear dsRNA Expression Library
[0118] Nuclear transcription vectors for use in library based
screening approaches to identify nucleic acids that modulate cell
function, gene expression, or the biological activity of a target
polypeptide are designed such that the target sequence is flanked
on one end by an RNA polymerase II promoter (for example, the
HCMV-IE promoter) and on the other end by a different RNA
polymerase II promoter (for example, the SCMV promoter). Other
promoters that can be used include other RNA polymerase II
promoters, an RNA polymerase I promoter, an RNA polymerase III
promoter, a mitochondrial RNA polymerase promoter, or a T7 or SP6
promoter in the presence of T7 or SP6 RNA polymerase, respectively,
containing a nuclear localization signal. Bacteriophage or viral
promoters may also be used. The promoters are regulated
transcriptionally (for example, using a tet ON/OFF system (Forster
et al., supra; Liu et al., supra; and Gatz, supra) such that they
are only active in either the presence of a transcription-inducing
agent or upon the removal of a repressor. A single chromosomal
integrant is selected for, and transcription is induced in the cell
to produce the nuclear dsRNA.
[0119] Those vectors containing a promoter recognized by RNA Pol I,
RNA Pol II, or a viral promoter in conjunction with co-expressed
proteins that recognize the viral promoter, may also contain
optional sequences located between each promoter and the inserted
cDNA. These sequences are transcribed and are designed to prevent
the possible translation of a transcribed cDNA. For example, the
transcribed RNA is synthesized to contain a stable stem-loop
structure at the 5' end to impede ribosome scanning. Alternatively,
the exact sequence is irrelevant as long as the length of the
sequence is sufficient to be detrimental to translation initiation
(e.g., the sequence is 200 nucleotides or longer). The RNA
sequences can optionally have sequences that allow polyA addition,
intronic sequences, an HIV REV binding sequence, Mason-Pfizer
monkey virus constitutive transport element (CTE) (U.S. Pat. No.
5,880,276, filed Apr. 25, 1996), and/or self splicing intronic
sequences.
[0120] To generate dsRNA, two promoters can be placed on either
side of the target sequence, such that the direction of
transcription from each promoter is opposing each other.
Alternatively, two plasmids can be cotransfected. One of the
plasmids is designed to transcribe one strand of the target
sequence while the other is designed to transcribe the other
strand. Single promoter constructs may be developed such that two
units of the target sequence are transcribed in tandem, such that
the second unit is in the reverse orientation with respect to the
other. Alternate strategies include the use of filler sequences
between the tandem target sequences.
[0121] Cytoplasmic Transcription Vectors for the Generation of a
Cytoplasmic dsRNA Expression Library
[0122] Cytoplasmic transcription vectors for use in library based
screening approaches to identifying nucleic acids that modulate
cell function, gene expression, or the biological activity of a
target polypeptide in a cell using PTGS are made according to the
following method. This approach involves the transcription of a
single stranded RNA template (derived from a library) in the
nucleus, which is then transported into the cytoplasm where it
serves as a template for the transcription of dsRNA molecules. The
DNA encoding the ssRNA is integrated at a single site in the target
cell line as described for the nuclear RNA expression library,
thereby ensuring the synthesis of only one species of dsRNA in a
cell, each cell expressing a different dsRNA species.
[0123] A desirable approach is to use endogenous polymerases such
as the mitochondrial polymerase in animal cells or mitochondrial
and chloroplast polymerases in plant cells for cytoplasmic and
mitochondrial (e.g., chloroplast) expression to make dsRNA in the
cytoplasm. These vectors are formed by designing expression
constructs that contain mitochondrial or chloroplast promoters
upstream of the target sequence. As described above for nuclear
transcription vectors, dsRNA can be generated using two such
promoters placed on either side of the target sequence, such that
the direction of transcription from each promoter is opposing each
other. Alternatively, two plasmids can be cotransfected. One of the
plasmids is designed to transcribe one strand of the target
sequence while the other is designed to transcribe the other
strand. Single promoter constructs may be developed such that two
units of the target sequence are transcribed in tandem, such that
the second unit is in the reverse orientation with respect to the
other. Alternate strategies include the use of filler sequences
between the tandem target sequences.
[0124] Alternatively, cytoplasmic expression of dsRNA for use in
library based screening approaches is achieved by a single
subgenomic promoter opposite in orientation with respect to the
nuclear promoter. The nuclear promoter generates one RNA strand
that is transported into the cytoplasm, and the singular subgenomic
promoter at the 3' end of the transcript is sufficient to generate
its antisense copy by an RNA dependent RNA polymerase to result in
a cytoplasmic dsRNA species.
[0125] Target Cell Line Development for Use with Cytoplasmic dsRNA
Expression Libraries
[0126] The target cell line, using the vector containing the G418
cassette, GFP, and loxP site is designed as described above.
[0127] Development of a Cytoplasmic dsRNA Expression Library
[0128] Double stranded RNA expression libraries are generated by
inserting cDNA or randomized sequences (as described herein) into
an expression vector containing a single nuclear promoter (RNA
polymerase I, RNA polymerase II, or RNA polymerase III), which
allows transcription of the insert sequence. It is desirable that
this nuclear promoter activity is regulated transcriptionally (for
example, using a tet ON/OFF system described, for example; by
Forster et al., supra; Liu et al., supra; and Gatz, supra), such
that the promoters are only active in either the presence of a
transcription-inducing agent or upon the removal of a repressor.
This ensures that transcription is not induced until episomal
copies of the vector(s) are diluted out. Vectors also contain a
selectable marker, such as the hygromycin resistance gene, and a
loxP site. The expression vectors are integrated into the target
cell line by methods previously described in this application using
Cre recombinase (other site-specific recombinative strategies can
be employed, as described previously).
[0129] At two days post-transfection, cells are subjected to
hygromycin selection using concentrations established in kill curve
assays. Surviving cells are cultured in hygromycin to select for
cells bearing integrated vectors and to dilute out episomal copies
of the vector(s). At this point transcription is induced, and a
single stranded RNA (ssRNA) species derived from the insert
sequence is transcribed in the nucleus from the nuclear promoter in
the inserted vector. The insert is designed such that the insert
sequences in the transcript are flanked by bi-directional promoters
of RNA bacteriophages (for example, Qbeta or MS2, RNA dependent RNA
polymerase promoters) or cytoplasmic viral RNA-dependent RNA
polymerase promoter sequences (for example, those of Sindbis or
VEEV subgenomic promoters). The nuclear transcript is translocated
to the cytoplasm where it acts as a template for dsRNA by an RNA
dependent RNA polymerase, which may be provided through
co-transfection of a vector that encodes an RNA-dependent RNA
polymerase. Alternatively, an integrated copy of the polymerase may
be used.
Example 2
Generation of Templates for In Vitro Transcription of dsRNA for
Non-Library Based Approaches for Identification of Nucleic Acids
Using PTGS
[0130] Nucleic acid sequences that modulate cell function, gene
expression in a cell, or the biological activity of a target
polypeptide in a cell may also be identified using non-library
based approaches involving PTGS. A single known nucleic acid
sequence encoding a polypeptide with unknown function or a single
nucleic acid fragment of unknown sequence and/or function can be
made into a double stranded RNA molecule. This dsRNA is then
transfected into a desired cell type and assayed for modulations in
cell function, gene expression in the cell, or the biological
activity of a target polypeptide in the cell, using methods
described herein. A modulation in cell function, gene expression in
the cell, or the biological activity of a target polypeptide in the
cell identifies the nucleic acid of the dsRNA as a nucleic acid the
modulates the specific cell function, gene expression, or the
biological activity of a target polypeptide. This non-library based
approach to nucleic acid identification is desirably used under
conditions that inhibit an interferon response or dsRNA stress
response. Such conditions are described in detail below.
[0131] Nucleic acid fragments generated, for example, by PCR or
restriction endonuclease digestion, encoding the respective target
sequences were used as templates for in vitro transcription
reactions. PCR fragments are superior to plasmid templates for the
synthesis of discrete sized RNA molecules. The PCR fragments
encoded at least 20-50 or 100 to 1000, for example, 500 to 600
nucleotides (nts) of the target sequence and were derived from the
target mRNA. Known target sequences were obtained from GenBank and
or other DNA sequence databases. Target sequences were also
obtained from cellular RNAs that were generated into cDNAs to
create a number of different dsRNA molecules. Accordingly, it is
possible that the sequence and/or function of the target sequence
was not known at the time the dsRNA was generated.
[0132] Templates for sense target RNAs were generated by placing
the bacteriophage T7 promoter at the 5' end of the target coding
strand while antisense RNA templates contained the T7 promoter at
the 5' end of the non-coding strand. This was achieved by encoding
the T7 promoter at the 5' ends of the respective PCR primers.
Alternatively SP6 promoters, or a combination of SP6 and T7
promoters may be used.
[0133] PCR was performed by conventional methods. The use of both
PCR templates in equimolar amounts in an in vitro transcription
reaction resulted in primarily dsRNA. The use of two separate
fragments has been found to be superior to the use of one PCR
fragment containing two T7 promoters, one located at each end of
the target sequence, presumably due to transcription interference
that occurs during transcription of the dual promoter template.
Following PCR amplification, the DNA was subjected to Proteinase K
digestion and phenol-chloroform extraction to remove, contaminating
RNases. Following ethanol precipitation, the DNA was resuspended in
RNase-free water at a concentration of 1 to 3 .mu.g/.mu.l.
[0134] As an alternative to phenol-chloroform extraction, DNA can
be purified in the absence of phenol using standard methods such as
those described by Li et al. (WO 00/44914, filed Jan. 28, 2000).
Alternatively, DNA that is extracted with phenol and/or chloroform
can be purified to reduce or eliminate the amount of phenol and/or
chloroform. For example, standard column chromatography can be used
to purify the DNA (WO 00/44914, filed Jan. 28, 2000).
Example 3
In Vitro RNA Transcription and RNA Analysis
[0135] In vitro transcription reactions are carried out using the
Riboprobe Kit (Promega Corp.), according to the manufacturer's
directions. The template DNA is as described above. Following
synthesis, the RNA is treated with RQ1 DNase (Promega Corp.) to
remove template DNA. The RNA is then treated with Proteinase K and
extracted with phenol-chloroform to remove contaminating RNases.
The RNA is ethanol precipitated, washed with 70% ethanol, and
resuspended in RNase-free water. Aliquots of RNA are removed for
analysis and the RNA solution is flash frozen by incubating in an
ethanol-dry ice bath. The RNA is stored at -80.degree. C.
[0136] As an alternative to phenol-chloroform extraction, RNA can
be purified in the absence of phenol using standard methods such as
those described by Li et al. (WO 00/44914, filed Jan. 28, 2000).
Alternatively, RNA that is extracted with phenol and/or chloroform
can be purified to reduce or eliminate the amount of phenol and/or
chloroform. For example, standard column chromatography can be used
to purify the RNA (WO 00/44914, filed Jan. 28, 2000).
[0137] dsRNA is made by combining equimolar amounts of PCR
fragments encoding antisense RNA and sense RNA, as described above,
in the transcription reaction. Single stranded antisense or sense
RNA is made by using a single species of PCR fragment in the
reaction. The RNA concentration is determined by spectrophotometric
analysis, and RNA quality is assessed by denaturing gel
electrophoresis and by digestion with RNase T1, which degrades
single stranded RNA.
[0138] An mRNA library is produced using Qbeta bacteriophage, by
ligating the mRNAs to the flank sequences that are required for
Qbeta replicase function (Qbeta flank or Qbeta flank plus P1),
using RNA ligase. The ligated RNAs are then transformed into
bacteria that express Qbeta replicase and the coat protein. Single
plaques are then inoculated into fresh bacteria. All plaques are
expected to carry transgene sequences. Each plaque is grown in
larger quantities in bacteria that produce the Qbeta polymerase,
and RNA is isolated from the bacteriophage particles.
Alternatively, if the Qbeta flank plus P1 is used to generate the
library (e.g., P1=MS2, VEEV, or Sindbis promoter sequences), these
vectors can be used to carry out the in vitro transcription along
with the cognate polymerase. The in vitro made dsRNA is then used
to transfect cells.
[0139] RNA Delivery
[0140] In vitro made dsRNA is directly added to the cell culture
medium at concentrations ranging from 50 .mu.g/ml to 500 .mu.g/ml.
Uptake of dsRNA is also facilitated by electroporation using those
conditions required for DNA uptake by the desired cell type. RNA
uptake is also mediated by lipofection using any of a variety of
commercially available and proprietary cationic lipids,
DEAE-dextran-mediated transfection, microinjection, protoplast
fusion, calcium phosphate precipitation, viral or retroviral
delivery, or biolistic transformation. The RNA is naked RNA or a
local anesthetic RNA complex. Modulation of cell function, gene
expression, or polypeptide biological activity is then assessed in
the transfected cells.
[0141] Some dsRNA sequences, possibly in certain cell types and
through certain delivery methods, may result in an interferon
response. During the screening methods of the present invention,
induction of an interferon response is not desired, as this would
lead to cell death and possibly to the prevention of gene
silencing.
[0142] One of the components of an interferon response is the
induction of the interferon-induced protein kinase PKR. Suppression
of the interferon response and/or the PKR response is desired in
the target cells. The dsRNA delivery methods described herein are
performed such that an interferon response or dsRNA stress response
is not included. It is recognized, however, that certain conditions
might present with an induction of the interferon response. To
prevent such a response, a number of other strategies may be
employed with any of the above described screening methods to
identify a nucleic acid that modulates cell function, gene
expression, or the polypeptide biological activity of a cell, as
described herein.
[0143] To prevent an interferon response, interferon and PKR
responses are silenced in the target cells using a dsRNA species
directed against the mRNAs that encode proteins involved in the
response. Desirably interferon response promoters are silenced
using dsRNA. Alternatively, the expression of proteins that bind
the interferon response element is abolished using dsRNA
techniques.
[0144] In an alternative strategy, interferon and PKR knockout cell
lines are created through approaches utilizing expression cassettes
that encode an antisense RNA and ribozymes directed to the cellular
mRNAs that encode the proteins involved in the response. Knockout
cells are created by standard gene knockout technologies using
homologous recombination to alter target sequences, using
homologous DNA alone, or as complexes of RecA protein and single
stranded DNA homologous to the target sequence(s). Interferon
response element (IRE) sequences, sequences that encode
transcription factors that bind IRE sequences, the promoter and/or
gene sequences that encode proteins in the PKR and interferon
response pathways are molecules that are targeted for knockout.
[0145] If desired, proteins involved in gene silencing such as
Dicer or Argonaut can be overexpressed or activated to increase the
amount of inhibition of gene expression (Beach et al., WO 01/68836,
filed Mar. 16, 2001).
Example 4
Cytoplasmic Transcription Vectors for Non-Library Based Approaches
to Nucleic Acid Identification Using PTGS
[0146] Double stranded RNA molecules for use in non-library based
methods for the identification of nucleic acids that modulate cell
function, gene expression of a target nucleic acid, or target
polypeptide biological activity in a cell can also be generated
through the use of cytoplasmic transcription vectors. Such vectors
are generated as now described.
[0147] The PCR fragments generated for in vitro transcription
templates, as described above, are inserted into a cloning vector
containing one T7 promoter located just outside the polylinker
region. Such a vector is pZERO blunt (Promega Corp.). The PCR
fragment is cloned into a restriction site in the polylinker in
such a way that the fragment's T7 promoter is distal to the
vector's promoter. The resulting vector contains the target
sequence flanked by two T7 promoters; transcription from this
vector occurs in converging directions. Convergent transcription is
desired for these intracellular vectors, due to the uncertainty of
getting sense and antisense vectors into the same cell in high
enough and roughly equivalent amounts. In addition, the local
concentration of antisense and sense RNAs with respect to each
other is high enough to enable dsRNA formation when the dual
promoter construct is used.
[0148] A hygromycin resistance cassette is cloned into the pZERO
blunt vector as well. The hygromycin resistance cassette contains
the hygromycin resistance gene under the control of the Herpes
Simplex Virus (HSV) thymidine kinase promoter and the SV40
polyadenlyation signal. The cassette is in a plasmid vector and is
flanked at both ends by a polylinker region enabling ease of
removal and subsequent cloning. Hygromycin selection was chosen
because of the rapidity of death induced by hygromycin as well as
extensive in-house experience with hygromycin selection.
Alternatively, other selection methods known to those skilled in
the art may be used.
[0149] The vectors are transfected into the desired cells using
standard transformation or transfection techniques described
herein, and the cells are assayed for the ability of the dsRNA
molecules encoded by the vectors to modulate cell function, gene
expression of a target nucleic acid, or the biological activity of
a target polypeptide, as described herein.
Example 5
Analysis of RNA from transfected cells
[0150] Regardless of whether a library based screening approach or
a non-library based approach was used to identify nucleic acid
sequences, in order to measure the level of dsRNA effector molecule
within the cell, as well as the amount of target mRNA within the
cell, a two-step reverse transcription PCR reaction was performed
with the ABI PRISM.TM. 7700 Sequence Detection System. Total RNA
was extracted from cells transfected with dsRNA or a plasmid from a
dsRNA expression library using Trizol and DNase. Two to three
different cDNA synthesis reactions were performed per sample; one
for human GAPDH (a housekeeping gene that should be unaffected by
the effector dsRNA), one for the target mRNA, and/or one for the
sense strand of the expected dsRNA molecule (effector molecule).
Prior to cDNA synthesis of dsRNA sense strands, the RNA sample was
treated with T1 RNase. The cDNA reactions were performed in
separate tubes using 200 ng of total RNA and primers specific for
the relevant RNAs. The cDNA products of these reactions were used
as templates for subsequent PCR reactions to amplify GAPDH, the
target cDNA, and/or the sense strand copied from the dsRNA. All RNA
was quantified relative to the internal control, GAPDH.
Example 6
Target sequence identification
[0151] To identify the target sequence affected by a dsRNA, using
any of the above-described methods, DNA is extracted from expanded
cell lines (or from the transfected cells if using a
non-integrating dsRNA system) according to methods well known to
the skilled artisan. The dsRNA encoding sequence of each integrant
(or non-integrated dsRNA molecule if using a non-library based
method) is amplified by PCR using primers containing the sequence
mapping to the top strand of the T7 promoter (or any other promoter
used to express the dsRNA). Amplified DNA is then cloned into a
cloning vector, such as pZERO blunt (Promega Corp.), and then
sequenced. Sequences are compared to sequences in GenBank and/or
other DNA databases to look for sequence identity or homology using
standard computer programs. If the target mRNA remains unknown, the
mRNA is cloned from the target cell line using primers derived from
the cloned dsRNA by established techniques (Sambrook et al.,
supra). Target validation is then carried out as described
herein.
[0152] In the stably integrated dsRNA expression system described
above, despite efforts to reduce negative position effects,
inefficient dsRNA synthesis by PCR methods may occur. This can be
circumvented by rescuing the integrated cDNA or randomized nucleic
sequences into replicating plasmids. Rescued plasmids are amenable
to amplification in bacteria and to sequencing. Rescue is achieved
by re-transfecting the population of cells transfected with the
dsRNA expression library with the rescue plasmid and a plasmid
encoding Cre recombinase. The rescue plasmid carries a bacterial
origin of replication, a bacterial antibiotic selection marker, an
SV40 origin of replication, and an SV40 T antigen expression
cassette, as well as loxP sites positioned as an inverted repeat to
allow Cre-mediated double recombination. The SV40-based origin of
replication in the rescue plasmid allows amplification of rescued
sequences in the integrated cells. Following rescue, higher levels
of transcription are anticipated, thereby favoring dsRNA formation.
The cells are then screened for modulations in cell function,
target nucleic acid expression, or target polypeptide biological
activity changes as described herein.
Example 7
Prevention of an Interferon Response During Gene Silencing
[0153] As discussed above, during the above-described screening
methods, induction of an interferon response is not desired, as
this would lead to cell death, anti-proliferative responses, and
possibly to prevention of gene silencing. One of the components of
an interferon response is the induction of the interferon-induced
protein kinase PKR. Suppression of the interferon response and/or
the PKR response is desired in the target cells. The dsRNA delivery
methods described herein are performed such that an interferon
response is not included. It is recognized, however, that certain
conditions might present with an induction of the interferon
response. To prevent such a response, a number of other strategies
may be employed with any of the above described screening methods
to identify a nucleic acid that modulates cell function, gene
expression, or the polypeptide biological activity of a cell, as
described herein.
[0154] To prevent an interferon response in a system involving
stable integration of the nucleic acid containing the dsRNA
expression cassette, the vectors used to generate either the loxP
integrant or the vector that encodes the dsRNA expression cassette
are designed to contain sequences that encode proteins that block
the PKR response, such as the Vaccinia virus protein E3 (Romano et
al., Molecular and Cellular Biology 18:7304-7316, 1998; Accession
No. M36339), or a cellular protein P58.sup.IPK, which the influenza
virus mobilizes to block PKR (Gale et al., Microbiology and
Molecular Biology Reviews 64:239-280, 2000; Accession No.
XM.sub.--032882). Several other viral proteins have also been
identified (e.g., Hepatitis C E2; Accession No. S72725) and may be
similarly used. These proteins can be expressed in the desired cell
types or in animals through the use of any of a number of
commercially available mammalian expression vectors or vertebrate
expression vectors. Such vectors can be obtained from a number of
different manufacturers including Invitrogen (Carlsbad, Calif.)
Promega ((Madison, Wis.), or Clontech (Palo Alto, Calif.). An
example of such a vector is the pCI-neo Mammalian Expression Vector
from Promega.
[0155] Regardless of whether nucleic acid encoding a dsRNA is
stably integrated into a chromosome or is not integrated into a
chromosome, the following methods may be used to prevent an
interference response in any of the screening methods of the
present invention. In one example of an interferon avoidance
strategy, interferon and PKR responses are silenced in the target
cells using a dsRNA species directed against the mRNAs that encode
proteins involved in the response. Desirably interferon response
promoters are silenced using dsRNA. Alternatively, the expression
of proteins that bind the interferon response element is abolished
using dsRNA techniques.
[0156] In an alternative strategy, interferon and PKR knockout cell
lines are created through approaches utilizing expression cassettes
that encode an antisense RNA and ribozymes directed to the cellular
mRNAs that encode the proteins involved in the response. Knockout
cells are created by standard gene knockout technologies using
homologous recombination to alter target sequences, using
homologous DNA alone, or as complexes of RecA protein and single
stranded DNA homologous to the target sequence(s). Interferon
response element (IRE) sequences, sequences that encode
transcription factors that bind IRE sequences, the promoter and/or
gene sequences that encode proteins in the PKR and interferon
response pathways are molecules that are targeted for knockout.
[0157] In yet another alternative, chimeric oligonucleotides may be
used to alter target sequences. Methods for inhibiting expression
of polypeptides through chimeric oligonucleotides are well known in
the art (Igoucheva and Yoon, Human Gene Therapy 11:2307-2312,
2000).
Example 8
Functional Screening for Cell Invasion
[0158] Cell invasion is one cell function that may be evaluated in
the search for novel genes that are modulated using the methods
described herein. Matrigel, a biological extracellular matrix, has
properties similar to that of a reconstituted basement membrane and
has been used to measure the invasive potential of tumor cells
(Platet and Garcia, supra). Cells transfected with randomized or
cDNA libraries that have been cloned into PTGS vectors are
monitored for their capacity invade matrigel invasion chambers.
Cells that have taken up sequences unrelated to invasion invade the
matrigel as efficiently as vector-transfected control cells. Cells
experiencing PTGS of genes that are involved in cell invasion
invade much less efficiently. If the dsRNA expression cassette is
stably integrated in a chromosome, these cells are retrieved and
second and third rounds of selection are carried out in order to
isolate specific nucleic acid sequences relevant to cell invasion.
The effect of these sequences on invasion is ultimately confirmed
by their ability to block the formation of tumors in animal
models.
[0159] Several human cell lines, for example, MDA-MB-231, used by
Platet and Garcia (supra), SKBr3, and MCF-7ADR, a more metastatic
variant of MCF-7. MDA-MB-231 breast cancer cells (obtained from the
American Type Culture Collection) are also transfected with cDNA
libraries or randomized nucleic acid libraries constructed into the
vectors described above. Desirably all cells in this assay contain
a single copy of a transfected gene, as described above.
[0160] Cells cultured in commercially available 24- or 96-well
formatted systems are used to carry out the cell invasion assay. As
this screening protocol relies-upon repeated rounds of selection,
it may be desirable to keep the cell numbers in each well low
enough that enrichment is seen in each succeeding round, yet high
enough to recover sufficient cells to culture within a reasonable
time period. Therefore, culture conditions that result in invasion
by greater than 50% of the cells and that still permit recovery
from the surface of the matrigel are made optimal. Non-invasive
(NIH3T3 cells) or poorly invasive (MCF7) cell lines are analyzed in
parallel as negative controls for invasion.
[0161] Initially, triplicate cultures of half-log order dilutions
from 10.sup.2 to 10.sup.6 cells per well are plated. Cells are then
recovered by "scrubbing" with a sterile cotton swab in fresh
culture media and are seeded into 96-well plates. The number of
invasive cells in the matrigel is quantified using either an
MTT-based assay (Sasaki and Passaniti, Biotechniques 24:1038-1043,
1998) or a fluorescent indicator (Gohla et al., Clin. Exp.
Metastasis 14:451-458, 1996).
[0162] Once the appropriate cell densities for the assay have been
empirically determined, stable transfected cells are plated in the
matrigel cell invasion chambers. Each experiment includes the
following controls: a sample of untransfected cells as a reference
culture; untransfected cells treated with anti-invasive
chemotherapeutic agents, such as taxol or doxorubicin, as a
positive control for inhibition of invasion; cells transfected with
empty vectors to confirm that the vector alone had no effects on
invasion; and cells transfected cells with genes that are known to
block invasion in this assay, such as estrogen receptor-.alpha. or
TIMP-2 (Kohn et al., Cancer Research 55:1856-1862, 1995; and
Woodhouse et al., Cancer (Supplement) 80:1529-1536, 1997).
[0163] Cells that fail to invade the matrigel are removed from each
well to the corresponding wells of a 96-well plate and cultured
until macroscopic colonies are visible. It is important to collect
cells at more than one time point after plating, since the time it
takes for PTGS to be effective may vary, and it may be that
different genes are active at different times after plating. Once
the cells are transferred to 96-well plates, they are diluted out
and taken through successive rounds of re-screening in the invasion
assay in order to expand and isolate cell lines with altered
invasive ability. As the population becomes more and more enriched
for cells with a non-invasive phenotype, the reduction in invasive
cells in the matrigel can be better quantified via MTT or
fluorescence assays. Ultimately, a large panel of cloned
double-stable cell lines is generated.
[0164] This assay can also be carried out with cells into which a
dsRNA is not stably integrated into a chromosome. The assay is
conducted essentially as described above except that multiple
rounds of selection and re-screening are not necessary since the
cell is transfected with only one dsRNA species. Thus, the
target(s) of the PTGS event is readily identifiable using the
cloning and sequencing techniques described above.
Example 9
Downregulation of HIV Using HIV-Derived dsRNA and Inhibitors of the
Interferon Response Pathway
[0165] During the course of HIV infection, the viral genome is
reverse transcribed into a DNA template that is integrated into the
host chromosome of infected dividing cells. The integrated copy is
now a blueprint from which more HIV particles are made. Several
cell lines that contain integrated copies of a defective HIV
genome, HIVgpt (strain HXB2) have been created. The HIVgpt genome
contains a deletion of the HIV envelope gene; all other HIV
proteins are encoded. The plasmid used to create these cell lines,
HIVgpt, was obtained from the AIDS Research and Reference Reagent
Program Catalog. Stably integrated cell lines were made with human
rhabdomyosarcoma (RD) cells. The lines were made by transfecting
cells with the plasmid followed by selection of cells in
mycophenolic acid. The HIVgpt genome encodes a mycophenolic acid
(MPA) resistance gene in place of the envelope gene and thereby
confers resistance to MPA. Cells resistant MPA were clonally
amplified. The media from the cultured clonally expanded cells was
assayed for the presence of p24 (an HIV gag polypeptide that is
secreted extracellularly). All cell lines were positive for p24, as
assessed using a p24 ELISA assay kit (Coulter, Fullerton, Calif.).
The cell lines also make non-infectious particles which can be
rescued into infectious particles by co-expression of an HIV
envelope protein.
[0166] The HIVgpt cell lines are used as a model system with which
to downregulate HIV expression via PTGS. Plasmids encoding a 600 nt
sense RNA, a 600 nt antisense RNA, or a 600 bp double stranded RNA
(dsRNA), mapping to the same coordinates of the gag gene of HIV
strain HXB2 are used to transfect cells (the map from which the
coordinates are based is found at GenBank Accession number K03455,
HIV(HXB2), complete genome, and the gag RNAs used in this study map
to coordinates 901-1500). Expression of the RNAs is from T7 RNA
polymerase promoter(s) located at the 5' end of the gag sense
strand, at the 5' end of the antisense strand, or at converging
positions at the 5' ends of both the sense and anti-sense strands,
respectively. These encoded RNAs are not designed to be able to
make protein (i.e., they do not have a cap, a poly A tail, or the
native initiation codon): Transcription of the RNAs is catalyzed by
T7 RNA polymerase, provided from a second co-transfected T7 RNA
polymerase expression plasmid. Control plasmids expressing a
similar sized sense RNA, antisense RNA, and dsRNA derived from the
gD gene of an HSV2 genome are included as experimental controls
(the map from which the coordinates are based is found at GenBank
Accession number K01408, HSVgD2 gene, and the HSVgD RNAs used in
this study map to coordinates 313-872).
[0167] Cells used in these studies are transfected with an
expression plasmid encoding a gene product known to interfere with
the dsRNA induced interferon response or with the PKR response, as
described above. The cells are transfected with lipofectamine
(Gibco-BRL) as a transfecting agent according to the manufacturer's
instructions.
[0168] Two days after transfection, the cells are harvested and
seeded into six-well plates and cultured to approximately 80 to 90%
confluence. Cells are co-transfected with the T7 RNA polymerase
expression plasmid and one of the RNA expression plasmids, such
that one well of cells receives the T7 RNA polymerase expression
plasmid and the gag sense RNA expression plasmid; one well of cells
receives the T7 RNA polymerase expression plasmid and the gag
antisense RNA expression plasmid; one well of cells receives the T7
RNA polymerase expression plasmid and the gag dsRNA expression
plasmid; one well of cells receives the T7 RNA polymerase
expression plasmid and the HSVgd sense RNA expression plasmid; one
well of cells receives the T7 RNA polymerase expression plasmid and
the HSVgd antisense RNA expression plasmid; and one well of cells
receives the T7 RNA polymerase expression plasmid and the HSVgD
dsRNA expression plasmid. Transfection is again mediated through
lipofectamine (Gibco-BRL). There also is a control group of cells
receiving no RNA. The cells are monitored for p24 synthesis over
the course of several weeks. The cells are assayed both by
measuring p24 in the media of cells (using the p24 ELISA kit from
Coulter, according to the manufacturer's instructions) and by
immunostaining fixed cells for p24 using a rabbit polyclonal
anti-p24 sera and anti-rabbit IgG that is FITC conjugated (Sigma).
None of the gD RNAs specifically shut down p24 synthesis. The
double stranded gag RNA significantly down regulates p24. The sense
and antisense have only a modest effect on p24 synthesis and some
of the effect is predicted to be through the ability of the sense
and antisense gag RNAs to generate low levels of dsRNA species.
Example 10
Downregulation of PSA Expression in Human Rhabdomyosarcoma Cells
Using Intracellular Expression of dsRNA
[0169] RD cells transiently expressing prostate specific antigen
(PSA) were transfected with a T7 RNA polymerase expression vector
and T7 RNA expression vectors expressing PSA dsRNA, PSA sense RNA,
PSA antisense RNA, or control RNAs. The ability of the expressed
RNAs to downregulate PSA expression was assessed, as described
further below.
[0170] Creation of a Transient PSA Expression Line
[0171] The ability to downregulate expression of PSA following the
expression of a PSA specific double-stranded RNA (dsRNA) was
demonstrated in a human rhabdomyosarcoma cell line. Since available
PSA cell lines are difficult to work with (i.e., they are hard to
transfect, and the cells tend to clump), a human cell line
transiently expressing PSA was created. To create these cells,
human rhabdomyosarcoma cells were transiently transfected with a
PSA plasmid-based expression vector, under conditions that result
in transfection of greater than 95% of the cells. Transfection was
mediated with lipofectamine transfecting reagent (Gibco-BRL)
according to the manufacturer's instructions. Expression of PSA was
directed by the HCMV-IE promoter and the SV40 polyadenylation
signal (FIG. 2). PSA expression was measured in the supernatant of
transfected cells using a PSA ELISA kit (Oncogene Science
Diagnostics, Cambridge, Mass.). No aPSA was detected in the
untransfected parental cells while PSA was abundantly expressed in
cells receiving the PSA expression vector.
[0172] Downregulation of PSA Expression
[0173] The PSA expressing cell line was used as a model system with
which to demonstrate the downregulation of PSA protein levels by
PTGS. In these studies, plasmids encoding an approximately 600 nt
sense RNA, a 600 nt antisense RNA or a 600 nt dsRNA derived from a
PSA cDNA were used to transfect the PSA expressing cell line (FIG.
2). Expression of the RNAs was from a T7 RNA polymerase promoter(s)
located at the 5' end of the PSA sense strand, at the 5' end of the
PSA antisense strand, or at converging positions at the 5' ends of
both the sense and antisense strands respectively (FIG. 2). These
encoded RNAs are not designed to be able to make protein (they do
not have a cap, or a poly A tail). Transcription of the RNAs was
catalyzed by T7 RNA polymerase, provided by a co-transfected T7 RNA
expression plasmid. Control plasmids expressing similar sized sense
RNA, antisense RNA, and dsRNA derived from the glycoprotein D (gD)
gene of an Herpes simplex 2 (HSV-2) genome, as described above were
included as experimental controls.
[0174] Cells used in these studies can optionally be transfected
with an expression plasmid encoding a gene product known to
interfere with the dsRNA induced interferon response or with the
PKR response, as described above. The cells are transfected with
lipofectamine (Gibco-BRL) as a transfecting agent according to the
manufacturer's instructions.
[0175] Human rhabdomyosarcoma cells were seeded into six-well
plates and cultured to approximately 80 to 90% confluence. The
cells were co-transfected with (A) the PSA expression plasmid; (B)
one of the T7 RNA expression plasmids; and (C) the T7 RNA
polymerase expression plasmid, such that all PSA expressing cells
were transfected with the T7 RNA polymerase expression plasmid and
one of the following: the T7 sense PSA RNA expression construct,
the T7 antisense PSA RNA expression construct, the T7 dsRNA PSA
expression construct, the sense HSVgD RNA expression construct, the
antisense HSVgD expression construct, or the dsRNA HSVgd expression
construct. Cells received identical amounts of the PSA expression
plasmid and the T7 RNA expression plasmid. The amounts of the T7
RNA expression plasmids were also constant amongst the transfected
cells. Total DNA per transfection was held constant at 2.5 .mu.g
DNA per one well of a six-well plate. In those transfections where
there was no T7 RNA expression plasmid, an inert plasmid DNA was
used as filler DNA. Transfection was mediated by lipofectamine
(Gibco-BRL) according to the manufacturer's instructions. There was
also a control group of untransfected cells, as well as an
untreated PSA control group of cells transfected with only the PSA
expression plasmid in combination with the T7 RNA polymerase
expression plasmid.
[0176] PSA-expressing cells that were not transfected with the T7
RNA expression plasmid, as well as cells transfected with the T7
HSV2-gDRNA expression plasmid all expressed PSA abundantly and at
comparable levels. Cells transfected with the sense, antisense, and
ds PSA RNA expression plasmids all exhibited varying degrees of
inhibition of PSA expression. A 5%-10% reduction in expression was
seen in cells expressing the PSA sense RNA, a 50% reduction was
seen in cells expressing the PSA antisense RNA and greater than 95%
reduction was seen in the cells expressing the PSA dsRNA (FIG. 3).
The inhibition was seen within two days after transfection and
continued up until the last time point taken (one month later) at
which point PSA levels were beginning to decline in the untreated
cells and the experiment was terminated. The untreated PSA controls
as well as cells transfected with the T7 HSV2-gD control RNA
expression plasmids all expressed PSA abundantly and at comparable
levels (FIG. 3), indicating the specificity of dsRNA effectors to
silence gene expression. During the one of month culture, cells
were expanded into larger cultures at routine intervals.
[0177] Although the PSA specific dsRNA induced significant
inhibition of PSA expression, antisense and sense PSA RNAs also
induced some level of inhibition. Antisense PSA RNA has the
potential to form dsRNA by annealing with PSA mRNA. Therefore the
inhibition seen with antisense RNA may be explained by both an
antisense mechanism and a dsRNA induced inhibition. A critical
intracellular conicentration of both antisense RNA and mRNA is
required to generate dsRNA. Since much less dsRNA is made in the
antisense RNA expressing cells relative to those cells designed to
make dsRNA, a lesser inhibition of PSA in the antisense RNA
expressing cells is expected if the threshold dsRNA levels required
for efficient silencing have not been reached in those cells. We
have also demonstrated that a small amount of antisense RNA can be
found in cells transfected with our expression vectors
(approximately 0.2% the amount of mRNA steady state levels).
Antisense expression is presumably driven by cryptic promoters on
the non-coding plasmid DNA strand. The observed sense RNA
inhibition could therefore also involve a dsRNA molecule. RNA from
transfected but untreated cells could also be analyzed to determine
if the low level expression of antisense RNAs in these cells
results in the production of detectable dsRNA species. Some low
level expression of PSA occurred in cells expressing PSA dsRNA. It
is likely that some percentage of cells did not take up the dsRNA
expression cassette or that the threshold levels of dsRNA were not
reached in some cells. No cellular toxicity was seen with any of
the dsRNAs generated by the RNA expression vectors suggesting that
cytoplasmic expression of dsRNA does not induce the interferon
response. In contrast, cell death is induced when certain
concentrations of in vitro produced dsRNA is delivered to cells via
transfection with certain cationic lipids.
[0178] In summary, these results indicate that (i) PSA derived
dsRNA is much more efficient than PSA antisense RNA in
down-regulating PSA expression, (ii) the down-regulation is
sequence specific; only the PSA derived dsRNA and not the control
HSV-2 derived dsRNA induced down-regulation of PSA, and (iii) there
is no toxicity associated with the cytoplasmic expression of long
(600 bp) dsRNA molecules. Additionally, these experiments are the
first demonstration of dsRNA mediated down-regulation of gene
expression in a human cell line.
Example 11
Intracellular Expression of dsRNA does not Induce the Type 1
Interferon Response (RNA Stress Response)
[0179] Human rhabdomyosarcoma (RD) cells were transfected with
various dsRNA expression vectors such that dsRNA was transcribed in
the transfected cells as described in Example 10. Transcription of
dsRNA occurred in the cells within 24 hours after transfection and
continued for the duration of the thirty day experiment. Cells and
the supernatants from transfected cells were analyzed during the
course of the experiment for any evidence of RNA stress response
induction. No evidence of RNA stress response induction by
intracellular expressed dsRNA was observed. RD cells have been
shown by us to be responsive to type 1 interferon, both alpha and
beta, and thus RD cells are capable of mounting an RNA stress
response. In addition, positive controls were included in these
experiments. A positive control for these experiments is a method
of delivering dsRNA which induces the RNA stress response. All
positive controls induced the RNA stress response. These
experiments are described further below.
[0180] Assays Performed to Identify RNA Stress Response
Induction
[0181] The following assays were performed to measure the induction
of an RNA stress response: TUNEL assay to detect apoptotic cells,
ELISA assays to detect the induction of alpha, beta and gamma
interferon, ribosomal RNA fragmentation analysis to detect
activation of 2'5'OAS, measurement of phosphorylated eIF2a as an
indicator of PKR (protein kinase RNA inducible) activation,
proliferation assays to detect changes in cellular proliferation,
and microscopic analysis of cells to identify cellular cytopathic
effects. Apoptosis, interferon induction, 2'5' OAS activation, PKR
activation, anti-proliferative responses, and cytopathic effects
are all indicators for the RNA stress response pathway.
[0182] Transfection of Cells
[0183] Approximately 7.times.10.sup.5 RD cells were seeded into
individual wells of six-well plates. Cells were transfected when
they reached about 90% confluency. Cells were transfected with a T7
RNA polymerase expression construct and a T7 dsRNA expression
construct. The T7 dsRNA expression constructs encode converging T7
promoters located on either side of a 600 bp sequence (FIG. 2).
Controls included cells transfected with the T7 RNA expression
construct alone so that no dsRNA is made in these cells. Total DNA
per transfection was held constant at 2.5 .mu.g DNA per one well of
a six-well plate. When the T7 RNA polymerase and T7 dsRNA
expression vectors were both used, 1.25 .mu.g of each DNA was used
per transfection. In those transfections where there was no T7
dsRNA expression construct, inert filler DNA was used to bring the
total DNA to 2.5 .mu.g per transfection. Transfection was mediated
using Lipofectamine (InVitrogen) according to the manufacturer's
directions. The positive control transfections included poly(I)(C)
RNA and in vitro transcribed dsRNA of 600 bp that were both
complexed with Lipofectamine and transfected into cells. The cells
were transfected with in vitro transcribed ssRNA complexed with
Lipofectamine. 2.5 .mu.g of each RNA was used per transfection.
Other controls included untreated cells. Cells were kept in culture
for one month by expanding into larger flasks as the cell numbers
increased.
[0184] ELISA Assays
[0185] Supernatants were removed from the transfected and untreated
cells at time points of 1, 2, 7, 17, and 48 hours and every several
days for up to one month after the 48 hour time point. Collected
supernatants were stored at -80.degree. C. until they were analyzed
for the presence of alpha, beta, and gamma interferon using
commercially available ELISA kits. The Interferon-alpha ELISA kit
was obtained from ENDOGEN (Rockford, Ill.), the Interferon-Beta
ELISA kit was obtained from RD1 (Flanders, N.J.), and the
Interferon-gamma ELISA kit was obtained from R&D Systems
(Minneapolois, Minn.). ELISAs were all performed according to the
manufacturer's directions. Alpha, beta, and gamma interferon were
not detected at nIt increased levels in cells expressing
intracellular dsRNA compared to the corresponding levels in
untreated cells. However, considerable levels of beta interferon
were found in cells transfected with poly (I)(C) or with in vitro
transcribed dsRNA and ssRNA. Alpha and beta interferon induction
are associated with induction of the RNA stress response.
[0186] TUNEL Assay
[0187] Cells were stained for the presence of apoptotic nuclei
using a commercially available kit, TdT FragEL, DNA Fragmentation
Detection Kit, In Situ Apoptosis Assay from Oncogene (Boston,
Mass.). Cells were stained according the manufacturer's directions.
Cells were stained at 2 hours, 7 hours, 17 hours, 2 days, 3 days, 4
days, and 5 days after transfection. There was no evidence of
apoptosis induced by intracellular expressed dsRNA at any of the
time points analyzed. However, the majority of cells transfected
with poly (I)(C) or with the in vitro transcribed dsRNA were
apoptotic by 17 hours after transfection. No evidence of apoptosis
was observed in the untreated cells or in cells transfected with
ssRNA. Apoptosis is an end result of the induction of the RNA
stress response pathway.
[0188] 2'5'OAS Activation
[0189] The activation of 2'5'OAS was determined by performing
ribosomal RNA fragmentation analysis. Briefly, following
transfection, total RNA was extracted from cells using standard
procedures. RNA was extracted at the following time points: 2
hours, 7 hours, 17 hours, 48 hours, 3 days, 4 days, and 5 days
after transfection. 5-10 jtg RNA was analyzed for each sample. RNA
samples were first denatured in formaldehyde/formamide RNA sample
buffer at 65.degree. C. for 10 minutes prior to being
electrophoresed through 0.5.times.TBE agarose gels. Ribosomal RNA
was visualized by staining with ethidium bromide followed by
ultraviolet transillumination. Ribosomal RNA fragmentation was
observed in cells transfected with poly (I)(C) and with the in
vitro transcribed dsRNA. No fragmentation was observed in the
untreated control cells, cells transfected with ssRNA, or in cells
expressing intracellular dsRNA. These results indicate that 2'5'OAS
was not activated by dsRNA when it was made intracellularly.
2'5'OAS activation is associated with induction/activation of the
RNA stress response pathway.
[0190] PKR Activation
[0191] The activation of PKR was determined by measuring the levels
of eIF2alpha phosphorylation. Briefly, cells were lysed at various
times after transfection (2 hours, 7 hours, 19 hours, 48 hours, 3
days, 4 days, and 5 days after transfection) and analyzed for
levels of phosphorylated and non-phosphorylated eIF2 alpha. The
protocol for lysing cells can be found in the following reference:
Zhang F. et al., J. Biol. Chem. 276(27):24946-58, 2001. This
analysis was performed as described for detecting PKR
phosphorylation except that antibodies specific for phosphorylated
and non-phosphorylated eIF2alpha were used. These antibodies are
available from Cell Signaling Technology (Beverly, Mass.).
[0192] Cytopathic Effect and Antiproliferative Responses
[0193] Cytopathic effect was assayed by analyzing cells
microscopically using a light microscope. Cells were analyzed at
daily intervals throughout the course of the experiment. Cytopathic
effect is defined as any or all of the following: cells detaching
from surface of well/flask, cells rounding up, an increased number
of S vacuoles in transfected cells with respect to the control
untreated cells, or differences in morphology of cells with respect
to the untreated control cells. No cytopathic effect was seen in
those cells expressing dsRNA intracellularly. Severe cytopathic
effects were seen in cells transfected with Poly (I)(C) or with
dsRNA made in vitro. Cytopathic effect is associated with the RNA
stress response.
[0194] Antiproliferative responses were assayed by measuring the
division rate of cells. The division rate is determined by counting
cell numbers using standard procedures. Cells were counted every
few days for the duration of the experiment. No antiproliferative
responses were seen in cells expressing dsRNA intracellulary.
Antiproliferative responses are associated with the RNA stress
response.
[0195] Summary of Results
[0196] The results of the above assays indicate that intracellular
expression of dsRNA does not induce the RNA stress response. The
cells that were used for these experiments were competent for RNA
stress response induction as was demonstrated by the ability of
cationic lipid complexed poly(I)(C) and in vitro transcribed RNA to
induce/activate all tested components of this response. In
addition, the cells were found to be responsive to exogenously
added interferon. These results imply that the cells used for these
experiments are not defective in their ability to mount an RNA
stress response and therefore can be used as predictors for other
cells, both in cell culture and in vivo in animal models. This
method described here, which does not induce the interferon stress
response, has been found to induce PTGS. This method therefore
provides a method to induce PTGS without inducing an undesired RNA
stress response.
[0197] Although these results were generated using a vector that
utilizes a T7 transcription system and therefore expresses dsRNA in
the cytoplasm, the vector system can be changed to other systems
that express dsRNA intracellularly. Similar results are expected
with these expression systems. These systems include, but are not
limited to, systems that express dsRNA or hairpin RNAs in the
nucleus, in the nucleus followed by transport of the RNAs to the
cytoplasm, or in the cytoplasm using non-T7 RNA polymerase based
expression systems.
Example 12
Optimization of the Concentrations and Relative Ratios of In Vitro
or In Vivo Produced dsRNA and Delivery Agent
[0198] The optimal concentrations and ratios of dsRNA to a delivery
agent such as a cationic lipid, cationic surfactant, or local
anesthetic can be readily determined to achieve low toxicity and to
efficiently induce gene silencing using in vitro or in vivo
produced dsRNA.
[0199] Summary of Factors Effecting Nucleic Acid/Cationic Lipid
Interactions
[0200] Cationic lipid DNA interactions are electrostatic.
Electrostatic interactions are highly influenced by the ionic
components of the medium. The ability to form stable complexes is
also dependent upon the intermolecular interactions between the
lipid molecules. At low concentrations, certain inter-lipid
interactions are preferred; at higher lipid concentrations, rapid
condensates are formed due to higher order interactions. Although
local interactions are similar in both of these instances (e.g.,
phosphoryl groups in the DNA and the charged cationic head group),
the long range and inter-lipid interactions are substantially
different. Similarly, structurally diverse variants can be obtained
simply by changing the charge ratio of the complex by mixing
varying amounts of cationic lipid with fixed concentrations of the
nucleic acid or vice versa. This variation in the structure of the
complexes is evidenced by altered physical properties of the
complexes (e.g., differences in octanol partitioning, mobility on
density gradients, charge density of the particle, particle size,
and transfectability of cells in culture and in vivo) (Pachuk et
al. DNA Vaccines--Challenges in Delivery, Current Opinion in
Molecular Therapeutics, 2(2) 188-198, 2000 and Pachuk et al., BBA,
1468, 20-30, (2000)). Furthermore, different lipids, local
anesthetics, and surfactants differ in their interactions between
themselves, and therefore novel complexes can be formed with
differing biophysical properties by using different lipids
singularly or in combination. For each cell type, the following
titration can be carried out to determine the optimal ratio and
concentrations that result in complexes that do not induce the
stress response or interferon response. At several of these
concentrations PTGS is predicted to be induced; however, PTGS is
most readily observed under conditions that result in highly
diminished cytotoxicity.
[0201] Complex Formation
[0202] dsRNA is either produced by in vitro transcription using the
T7 promoter and polymerase or another RNA polymerase, such as an E.
coli RNA polymerase dsRNA can also be produced in an organism or
cell using endogenous polymerases.
[0203] Concentrations of dsRNA, such as PSA-specific dsRNA, are
varied from 1 .mu.g to 10 .mu.g. In some instances, 150 ng of a
plasmid that encodes a reporter of interest (PSA) to be silenced
may be comixed at a concentration between 10 ng and 10 g. The
concentration of cationic lipid, cationic surfactant, local
anesthetic, or any other transfection-facilitating agent that
interacts with the nucleic acid electrostatically are varied at
each of the dsRNA concentrations to yield charge ratios of 0.1 to
1000 (positive/negative) (i.e., the ratio of positive charge from
lipids or other delivery agents to negative charge from DNA or
RNA). The complexes are prepared in water or in buffer (e.g.,
phosphate, HEPES, citrate, Tris-HCl, Tris-glycine, malate, etc. at
pH values that range from 4.0 to 8.5), may contain salt (e.g.,
1-250 mM), and may contain glycerol, sucrose, trehalose, xylose, or
other sugars (e.g., mono-, di-, or polysaccharide). The mixture is
allowed to sit at room temperature, desirably for 30 minutes, and
may be stored indefinitely. The complexes are premixed in serum
free media. The nucleic acid and the transfecting reagent may be
mixed either through direct addition or through a slow mixing
process, such as across a dialyzing membrane or through the use of
a microporous particle or a device that brings the two solutions
together at a slow rate and at low concentrations. In some
instances, the two interacting components are mixed at low
concentrations, and the final complex is concentrated using a
diafilteration or any other concentrating device. Alternatively, if
the complexes are formed at high concentrations of either or both
of the interacting components, the complexes may be diluted to form
an ideal transfection mixture.
[0204] Transfection Protocol and Analysis of dsRNA Stress
Response
[0205] Complexes are added to cells that are .about.60-80%
confluent in serum free media. The complexes are incubated for
various times (e.g., 10 minutes to 24 hours) with the cells at
37.degree. C. and diluted with serum containing media or washed f1
and replated in serum free media. The cells are monitored for
toxicity and fr analyzed at various times for signs of dsRNA
response (e.g., TUNNEL assay to detect nicked DNA, phosphorylation
of EIF2alpha, induction and activation of 2'5' OAS, or
interferon-alpha and beta). Transfection conditions that result in
less than 50%, 25%, 10%, or 1% cytotoxicity or that result in a
less than 20, 10, 5, 2, or 1.5-fold induction of a stress response
are analyzed to determine if PTGS was efficiently induced.
[0206] Determining Induction of PTGS
[0207] PSA protein levels are determined in cell culture media
using standard methods. The data is normalized to the number of
live cells in culture to determine the concentrations required to
induce PTGS.
[0208] Results
[0209] Using the above method, cationic lipid complexes of dsRNA
induced toxicity at certain ranges. With lipofectamine as the
cationic lipid, positive to negative charge ratios greater than 10
did not produce any detectable toxicity at any of the
concentrations of dsRNA tested and induced a high level of PTGS,
resulting in highly decreased levels of PSA in the culture medium.
The RNA concentration ranges tested were 1 pg to 100 ng with a
constant amount of lipofectamine (10 uL of a 2 mg/mL solution from
GIBCO-BRL Life Technologies, Bethesda, Md.).
Example 13
Method to Avoid dsRNA Mediated Activation of the RNA Stress
Response Pathway
[0210] One or more components of the RNA stress response pathway
can be mutated or inactivated to avoid induction/activation of the
component(s) by dsRNA that is delivered to the cell or animal for
the purpose of inducing PTGS. These components, such as those
illustrated in FIG. 4, can be knocked out singularly or in
combination.
[0211] Various standard methods can be used to knockout components
of the RNA stress response pathway, such as PKR, human beta
interferon Accession No. M25460), and/or 2'5'OAS (Accession No.
NM.sub.--003733). Alternatively or additionally, one or more
interferon response element (IRE) sequences can be mutated or
deleted using a knockout construct designed based on the IRE
consensus sequence (Ghislain, et al., J Interferon Cytokine Res.
2001 Jun. 21(6):379-88), and/or one or more transcription factors
that bind IRE sequences, such as STAT1 (Accession number
XM.sub.--010893), can be mutated or deleted. These methods include
the use of antisense DNA/RNA, ribozymes, or targeted gene knockout
technology mediated by homologous recombination. One skilled in the
art is able to design the appropriate antisense sequences,
ribozymes, and vectors for targeted knockouts. For example,
targeted knockouts may be prepared by any of the following standard
methods: Shibata et al., Proc Natl Acad Sci USA. 2001 Jul. 17;
98(15):8425-32. Review, Muyrers et al., Trends Biochem Sci. 2001
May; 26(5):325-31, Paul et al., Mutat Res. 2001 Jun. 5;
486(1):11-9, Shcherbakova et al., Mutat Res. 2000 Feb. 16;
459(1):65-71, Lantsov. Ideal gene therapy: approaches and prospects
Mol Biol (Mosk). 1994 May-June; 28(3):485-95, in Gene Transfer and
Expression--A Laboratory Manual editor: Michael Kriegler,
Publisher--WH Freeman & Co, New York, N.Y., pages 56-60,
1990).
[0212] Knockout cells can be readily identified either through the
use of an antibiotic resistance marker which when transferred to
the chromosome confers resistance to the cell or through the use of
dsRNA itself. In particular, dsRNA (e.g., a high concentration of
dsRNA) induces apoptosis in wild-type cells while mutant cells
survive dsRNA treatment because they cannot mount a stress
response. Yet another approach involves performing the
dsRNA-induced PTGS experiment in the presence of large
concentrations of IRE (dsDNA) oligo, which is expected to titrate
activated STAT proteins. These oligos can be delivered
intracerllularly using transfecting agents or electroporation.
[0213] In another method of preventing the interferon response,
cells (e.g., RD cells) are transfected with a T7 RNA polymerase
expression vector and a T7 dsRNA expression vector encoding dsRNA
homologous to the human protein kinase PKR cDNA (accession number
M35663) or homologous to the coding sequence of any other component
in the RNA stress response pathway. In one particular example,
dsRNA corresponding to nucleotides 190-2000 is encoded by the
T7dsRNA expression vector. The expression vectors are similar to
those described in Example 10 and shown in FIG. 2, except that the
dsRNA encoding sequence is derived from the human protein kinase
PKR cDNA. Transfection in RD cells is performed as described in
Example 10. Within 2-5 days post-transfection, the cells are
functionally PKR negative.
Other Embodiments
[0214] From the foregoing description, it will be apparent that
variations and modifications may be made to the invention described
herein to adopt it to various usages and conditions. Such
embodiments are also within the scope of the following claims.
[0215] All publication, patents, and patent applications mentioned
in this specification are herein incorporated by reference to the
same extent as if each individual publication, patent, or patent
application was specifically and individually indicated to be
incorporated by reference.
* * * * *
References